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Exponentially increased numbers of publication covering click chemistry have proved its significance 
and versatility in interdisciplinary studies. Numerous scientific fields including material science, 
medicinal chemistry, and bioconjugate chemistry get support of click chemistry to explore profound 
researches. Certain chemical reactions eliciting high yield in mild conditions are categorized as click 
reactions such as strained ring opening by nucleophiles, non-aldol type carbonyl chemistry, thiol-
ene/yne reaction, and Diels-Alder reaction. Especially, azide and alkyne functional groups are 
biologically and chemically compatible, orthogonal to each other, and small to introduce in various 
complexes. These properties prompt exploration to expand cross-coupling pools. Copper catalyzed 
azide–alkyne cycloaddition is favorably selected in click reaction toolbox, because of the broad 
substrate scope, high yield, regioselectivity, and mild reaction conditions. Strain-promoted azide–
alkyne cycloaddition, utilizing ring strain energy, have also been spotlighted as an alternative method 
to evade toxic metal and increase the biocompatibility. Transition metals are good candidates in cross-
coupling reactions. Ruthenium catalyzes azide–alkyne cycloaddition to access selective 1,5-
disubstituted 1,2,3-triazoles, isomers of 1,4-disubstituted triazoles, prepared by copper click reactions. 
But harsh conditions such as organic solvents and elevated temperatures, disrupt its wide usage in 
interdisciplinary studies. 
In chapter 2, I utilized copper click reactions to formulate iron oxide nanoparticles including small 
molecules, imidazoquinoline derivatives. Adjuvant conjugated iron oxide nanoparticles have 
multivalent effects on immune responses compared to individual doses. Covalent conjugation of 
nanoparticles facilitate quantitative analysis and fluorescence tracking to dendritic cells. Chapter 3 
includes establishments of nickel catalyzed cycloadditions. Highly regioselective 1,5-disubstituted 
triazoles are synthesized by mixing nickelocene and Xantphos ligands under room temperature and 
aqueous media. Wide substrate scope and certain evidence of active catalysts are described and 
characterized by various analytical methods such as NMR, MS, XRD, and EPR. In the last chapter, we 
explored cross-coupling between organic azide and cyanoalkynes to prepare 4-cyano-1,5-disubstituted 
1,2,3-triazoles using nickelocene/Xantphos complex. Enhanced reaction conditions and broad 
substrates tolerance proved its versatility and reactivity comparison between cyanoalkynes and terminal 
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1.1. Click Chemistry 
The concept of “click chemistry” was firstly devised by K. Barry Sharpless with several criteria to 
categorize powerful and selective cross-coupling reactions. Click reactions should be modular, give a 
broad substrate scope, afford excellent yields, and be stereospecific. By these principles, reactions have 
furnished simple reaction conditions, product isolation (non-chromatographic methods), readily 
available reagents, and benign solvents such as water.1 Corresponding rigid acceptance standards secure 
facile accessibility to interdisciplinary studies. It exerts tremendous influence on various scientific fields 
including material science, pharmaceutical science, and chemical biology. Exponentially increased 
numbers of publication containing the concept have proved their impact and versatility (Figure 1.1). 
 
 








Generally, there are four types of practical click reactions: (i) strained ring (epoxide, aziridine) opening 
by nucleophiles, (ii) non-aldol type carbonyl chemistry forming amides, oximes and isoureas, (iii) 
addition of thiols to carbon–carbon multiple bonds (thiol-ene/yne reaction), and (iv) cycloaddition 
including Huisgen cycloaddition and Diels-Alder reaction (Scheme 1.1). 
 
Scheme 1.1. Representative examples of click reaction. 
 
Nucleophilic substitution could be applied in various strained rings such as epoxides, aziridines, and 
aziridinium ions.2-4 Strong strain energy called spring-loaded electrophiles are stored in three membered 
heterocycles, subsequent nucleophilic attack facilitates ring opening under mild conditions easily with 
released energy. Nucleophiles including azides, nitriles, and acetates are potential candidates to be 
inserted with high yield in alcohol or water solvents. Non-aldol type carbonyl chemistry affords high 
yields, and chemoselectivity under aqueous solvents. Primary amines could be coupled with carbonyl 
functional group for amide or isourea formation. Hydroxyl amine or hydrazine can undergo nucleophilic 
attack on carbonyl compounds, eliciting the formation of corresponding oximes or hydrazones.5,6 
Reactions are mainly applied in polymer synthesis and bioconjugate chemistry.7,8  
 Thiol-ene chemistry has been broadly studied and applied in early 2000. Two pathways are popular 
adding free-radicals by light or radical initiator like 2,2’-azobis(isobutyronitrile), and Michael addition 
in the presence of nucleophiles or bases.9,10 Usage of unique starting materials and mechanism occupied 
a certain area in photo-click chemistry and biomolecule conjugation including thiol group. 
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Azide−alkyne cross coupling and Diels-Alder reactions are representative pericyclic reactions in click 
chemistry. Diels-Alder reaction, introduced by Otto Diels and Kurt Alder, is a [4+2] cycloaddition to 
form six membered rings by conjugation of electron-rich dienes and electron-deficient dienophiles 
without any additional reagents. Substrate candidates are broad including furan, 1,3-cyclopentadiene, 
tetrazine for dienes, and maleimide, vinyl ketones, cyclooctene for dienophiles (Figure 1.2). Its high 
yields, regio- and stereo-selectivity fulfill requirements to be click reaction, but competition with retro 
Diels-Alder reaction at high temperature remains challenges.11 
 
Figure 1.2. (A) Well-known Diels-Alder reactions, (B) Schematic representation of polymer 
synthesis.12  
 
Copper (I)-catalyzed Azide−Alkyne Cycloaddition (CuAAC), firstly reported by Morten Meldal,13 and 
K. Barry Sharpless14 independently on 2002, is 1,3-dipolar cycloaddition to access 1,4-disubstituted 
1,2,3-triazoles. CuAAC is one of premier click reaction, satisfying all strict criteria with excellent 
functional group tolerence. Active catalytic species to achieve corresponding cycloaddition are copper 
(I) species, which is unstable in air conditions. Alternatively, combination of copper (II) species and 
reducing agents such as sodium ascorbate is a typical route to make Cu1+ in situ. With the continuous 
and profound studies, reaction conditions and possible entries are enhanced, and many relevant triazole 
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synthetic methods are developed to be applied in chemical biology. Detailed description of CuAAC 
about mechanism are stated on section 1.2.1, and I would briefly explain a metal-free cycloaddition in 
this section. 
Although CuAAC is a powerful method in click chemistry toolbox, existence of copper metal could 
be potential hindrance in biological study because of its toxicity. Metal-free click chemistry is developed 
to solve cytotoxicity issue. Strain-Promoted Azide−Alkyne Cycloaddition (SPAAC), a representative 
biorthogonal reaction, is designed by Carolyn R. Bertozzi in 2004.15 Reaction utilized cyclooctyne, 
which has massive angle deformation 163o, giving intrinsic ring strain nearly 18 kcal/mol.16 These high 
ring strain facilitates azide conjugation in physiological temperature without copper species. The 
absence of toxic metals affords in vivo metabolic studies including labeling fluorescence or drugs to 
complex cells. But the approach has still suffered from slow reaction kinetics, poor solubility, and 
regiospecificity. Development of useful cyclooctynes from aliphatic or fluoro-containing to 
dibenzoannulated form have studied to reduce reaction time and increase solubility for SPAAC 
versatility (Figure 1.3).16,17  
 







As the concept of click chemistry implies, there are enormous applications through wide scientific fields. 
Roughly, I could categorize applications as three major fields, material science, medicinal chemistry, 
and bioconjugate chemistry. Click reactions fulfill essential elements in polymer synthesis such as 
simplified experimental procedure and isolation with high yield. Conceptually, step-growth 
polymerization, self-oligomerization and cross-coupling, depicted in Scheme 1.2, are frequently 
achieved by the introduction of CuAAC. Step-growth approaches require two distinct functional groups 
or one functional group with different reactivity. Converting halogen group to azide is a core step to 
attain step-growth (Scheme 1.2A). Thiol−ene chemistry also gets attention in metal and solvent-free 
conditions with various forms including star,18 and branched19 oligomers. 
 
 
Scheme 1.2. (A) Schematic representation of convergent dendrimer synthesis.20,21 (B) Examples of click 
polymerization using various monomers such as AB2, A2+B3, A2+B2.22 
 
As the potential of molecular machine become realized,23,24 preparation of interlocked molecules such 
as rotaxanes, and catenanes gets spotlighted in supramolecular chemistry. Based on conceptual 
methodologies (capping, clipping, active metal template), various covalent reactions including ring-
closing olefin metathesis25 have contributed to building architectures. Click reactions are powerful 
surrogates because of their intrinsic properties (e.g., orthogonality, high yielding, and functional group 
tolerance). CuAAC is a favorably invited reaction in building and modifying interlocked molecules. 
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Active-metal template for rotaxane synthesis by CuAAC was achieved in 2006 (Figure 1.4A).26 
Tetrakis(acetonitrile)copper(I) hexafluorophosphate was chelated to nitrogen-containing macrocycles. 
Following azides and alkynes were coordinated to the copper complex, eliciting interlocked molecules 
after desorption of metal complex. Various substrates have been studied to reduce non-interlocked 
triazoles.27 Similar methodology under high temperature was applied in the synthesis of [2]catenanes, 
but relatively low yields are still challenges.28 
 
Figure 1.4. Schematic synthetic representations of (A) rotaxane,27 and (B) catenane.28 
 
A concept of bioorthogonal chemistry, focusing reactions in living systems, has many overlapped 
portions with click chemistry.29 It emphasizes biological inertness and compatibility with basis of high 
yield, selectivity, and speed. Those chemistry have shown great performance in bioconjugate chemistry 
which makes covalent bonds in vivo or in vitro between chemicals and biomolecular frameworks to 
study cellular events by tracking biomolecular probes, and make enhanced or multifunctional 
complexes. Various biomolecules including protein, glycans, lipids, genes, or even cells are candidates 
to be conjugated in reaction toolbox (e.g., Staudinger ligation, aldehyde condensation, CuAAC, SPAAC, 
Diels-Alder reaction) with profound consideration of purposes, selectivity, toxicity, rate, and 
circumstances. 
After choosing suitable reaction, next step is an installation of biorthogonal motifs to biomolecules 
among several methods. Direct chemical modification is a straightforward method introducing 
biorthogonal motifs directly. Introduction of linkers is also an alternative method linking amino acid 
residues (e.g., lysine, cysteine) and clickable functional groups.30 N-hydroxysuccinimide (NHS) could 
connect between lysine and orthogonal motif, and maleimide could connect cysteine and corresponding 
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motif.31 Non-specific modification because of their intrinsic abundance is a critical issue. Other option 
is introduction of unnatural amino acids. Amino acids having orthogonal motifs could be expressed 
through solid-phase peptide synthesis or metabolic labeling. Unnatural amino acid–specific mutant 
aminoacyl-tRNA synthetase (UAARS)/tRNA pairs help mutagenesis with genetically encoded amino 
acids. Techniques have been developed to widen substrates starting from small functional groups to 
large motifs, cyclooctynes.32,33 
 
Figure 1.5. Schematic representation of metabolic labeling and SPAAC.34 
By the metabolic engineering, unnatural moieties could be introduced onto cell surface easily. Figure 
1.5 showed metabolic labeling of tetra acetyl-N-azidoacetylmannosamine.34 With the skillful derivative 
preparation, chemical reporters could be decorated only on tumor cell. SPAAC including cargoes such 







1,2,3-triazoles are five-membered heterocycles, containing three nitrogen and two carbon atoms. 
Aromatic cores are chemically stable towards hydrolysis, oxidative, and reductive conditions. A 
hydrogen bond donor (C-H bond in a triazole) and two hydrogen bond acceptors (lone pairs of nitrogen 
in a triazole) induce high dipole moments,35,36 resulting in strong hydrogen bonds and π stacking 
interactions. There are many examples employing corresponding properties in functional material 
synthesis37-40 and especially on medicinal chemistry. 1,2,3-triazoles are representative non-classical 
bioisosters of the amide group (Figure 1.6).41-43 1,4-disubstituted triazoles have slightly longer distance 
and strong dipole moments compared to trans amide bonds, but their resembled structures motivated 
triazoles as potential surrogates of corresponding amides. Similar relationship exists between 1,5-
disubstituted triazoles and cis amide bonds. Figure 1.6B shows synthetic attempts in peptidomimetics 
to surrogate amino acids by artificial conjugation.44-47 There are several synthetic 1,2,3-triazoles for 
amide-bond isosteres, and bioactive molecules for anti-cancer, anti-viral, anti-bacterial, anti-microbial 
activities. (Figure 1.7 and 1.8).48,49 
 
Figure 1.6. (A) Structures of 1,4- and 1,5-disubstituted triazoles, and trans and cis amide bonds. (B) 




Figure 1.7. Structures of 1,2,3-triazoles to depict amide bonds.48 
 
 








Lots of versatile potential of the 1,2,3-triazole motifs elicits the development of facile synthetic methods 
conducted under simple reagents and conditions. Azides and alkynes are universal building blocks to 
access 1,2,3-triazoles, leading to massive progress over 50 years (Figure 1.9). Huisgen cycloaddition is 
almost firstly established approach by Rolf Huisgen in 1960s.50,51 Triazoles could be formed by simple 
heating two starting materials, but reaction has suffered from poor selectivity, generating 1,4-
disubstituted isomers and corresponding 1,5-isomers as 1 : 1 ratio. Strategies using metal catalysts could 
conquer the challenging regiocontrol, producing pure 1,4-isomers by copper, and 1,5-isomers by 
ruthenium. 
 
Figure 1.9. Remarkable synthetic approaches in azide−alkyne cycloaddition. 
 
1.2.1. Synthesis of 1,4-disubstituted 1,2,3-triazoles 
To access 1,4-disubstituted triazoles, there are two main streams utilizing metal catalysts or metal free 
approaches to avoid toxicity of the metal. In metal-free methodology, Amine and α,α-
dichlorotosylhydrazone can be conjugated by the help of base, or I2 and tert-butyl peroxybenzoate 
(TBPB), encouraged from Sakai reaction.52-54 Enamine/enolate (in situ generated by mixing aldehyde 
and secondary amine/tertiary amine) also induce cross coupling with aryl azides under mild 
conditions.55,56 These approaches are suffered from the narrow substrate scope. For general and handy 





As I mentioned above, CuAAC has become popular in various disciplines because of their convenience 
and effectivity. Figure 1.10 portraits proposed mechanistic cycles based on density functional theory 
(DFT) calculation and experimental evidence about intermediates. 
 
Figure 1.10. Proposed mechanism of CuAAC explained by (A) mononuclear and (B) dinuclear copper 
intermediate, (C) Representative water soluble chelating ligands. 
Reactive copper(I)-acetylides are conjugated with organic azide, following formation of 1,4-
disubstituted triazoles, but the matter is numbers of copper participated in. At the early stage, trials to 
explain CuAAC with one copper metal were predominant. It’s quite straightforward process, 
substituting a copper complex by deprotonation of the alkyne in the presence of base.14,57 However later 
studies based on kinetic study,58 and mass analysis59 suggested the possibility that two different copper 
centers are participated as σ-bound ligand and π-complexation during CuAAC.60 Weak π-complexation 
could help decrease of electron density of copper-acetylide, overcoming an activation barrier. Valery V. 
Fokin showed experimental evidence that existence of exogenous copper(I) could elicit azide and 
copper-acetylide conjugation.61 But it’s still dangerous to select dinuclear mechanism as the only answer 





Copper(I) salts catalyze azide−alkyne cycloaddition under the inert atmosphere and organic solvents. 
To facilitate copper-acetylide complex and stabilization, nitrogen bases such as trimethylamine, 2,6-
lutidine, and N,N-diisopropylethylamine are mandatory, even if homo-coupled alkynes are formed as 
side products. There are many examples utilizing copper such as CuI,13 CuBr,63 [CuBr•SMe2]2,64 and 
CuTC.65 In situ preparation of copper(I) species by mixing copper(II) metals CuSO4•5H2O and reducing 
agents, sodium ascorbate could supply opportunity to relieve the efforts to exclude air and moisture. 
Application to aerobic conditions are performed with addition of chelating ligands based on 
tris(triazolymethyl)amine derivatives and sulfonated bathophenanthrolines, which stabilize oxidation 
state of copper(I) metal, and accelerate cycloaddition reactions (Figure 1.10C).66-69 
Cu(OAc)2 are potential surrogates of CuSO4 in certain circumstances. On the basis of two precedent 
observations that copper(II) become active copper(I) in alcoholic media70 and copper(II) complex could 
preferably chelated to azide having auxiliary nitrogen donors, 2-picolylazide and alkynes are conjugated 
exceptionally rapidly in catalytic Cu(OAc)2 and alcohol solvents.71,72 Furthermore, chemoselective 
sequential CuAAC could be easily accomplished under mild conditions (Figure 1.11).73 
 
 
Figure 1.11. (A) Unsymmetrical biazide preparation. (B) Schematic representation of sequential 
CuAAC. 
 
Wide investigation to surrogate copper metal found different metals such as gold (on Au(111)),74 
ruthenium (e.g., RuH2(CO)(PPh3)3, RuCl2(PPh3)3),75,76 and Raney nickel.77 Silver catalyzed 
azide−alkyne cycloaddition (AgAAC) showed remarkable results.78,79 Silver(I) metal-P,O ligand 
complex (AgOAc with 2-diphenylphosphino-N,N,-diisopropylcarboxamide) could induce 
deprotonation of alkyne, resulting in silver(I) acetylide. After that, similar mechanistic pathway could 
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be drawn as copper cycles. Combination of AgN(CN)2 and N,N-diisopropylethylamine (DIPEA) 
relieved reaction conditions with the broad substrate scope under water/ethylene glycol co-solvents.80 
 
1.2.2. Synthesis of 1,5-disubstituted 1,2,3-triazoles 
Traditionally, metal acetylides, formed by stoichiometric lithium, magnesium, or zinc addition, could 
be cyclized with organic azide under inert atmosphere.81-83 But huge amounts of byproduct and harsh 
reaction conditions strongly require enhanced methodology to access 1,5-disubstituted triazoles. 
Various methodology have competed and challenged to get the title “biocompatible” by escaping usage 
of heavy metal. By mimicking cis-locked amide bonds, polymer-bound α-keto stabilized phosphorus 
ylides could spontaneously conjugate aryl azides.84,85 High yield, selectivity, and exclusion of artificial 
alkyne are advantageous, but poor functional group tolerance on azide has limited its widespread 
application. In 1,5-diaryl-substituted 1,2,3-triazole preparation, base promoted azide alkyne 
cycloaddition could be best option with high yield, and no byproduct. Aryl acetylenes become aryl 
acetylides with hydroxide or alkoxide in DMSO, following nucleophilic attacks on aryl azides to form 
triazoles. There is a multicomponent cascade reaction of amine, propynone, tosyl azide, and base by 
Michael addition/deacylative diazo transfer/cyclization sequence.86 
Compared to CuAAC, there were no general methods in exclusive preparation of 1,5-disubstituted 
triazoles. In 2005, ruthenium-catalyzed azide−alkyne cycloaddition (RuAAC) was founded by Valery 
V. Fokin and Guochen Jia.87 After screening various ruthenium(II) metals, they found pentamethyl-
cyclopentadienyl ruthenium complex (e.g., Cp*RuCl(PPh)3, Cp*RuCl(COD), [Cp*RuCl]4) catalyzed 
cross coupling, showing functional group tolerance with high yield and selectivity. Continuous studies 
have extend a substrate scope and reaction conditions, including catalyst species, amounts (1% to 10%), 
temperature (rt to 80℃), and solvents (e.g., benzene, dioxane, THF, DMF).88-93 
Both computational calculation based on DFT and experimental analysis including NMR, MS, XRD 
have complementary supported proposed RuAAC mechanism (Figure 1.12).88,94 Alkynes and azides are 
introduced by displacement of two spectator L type ligands forming intermediate a with electron-rich 
ligand Cp*, which stabilizes higher formal oxidation states. Figure 1.12B represents four possible metal 
complexes in alkyne and azide coordination. Complex a is a most favored orientation, when electronic 
and steric issues are considered, resulting lowest-energy pathway calculation. Following oxidative 
coupling to form a ruthenacycle and reductive elimination could finish the catalytic cycle of RuAAC. 
Steven P. Nolan suggested systemic study of general unsaturated 16 electrons ruthenium complex 
Cp*Ru(L)X.95 They provided guidelines in choosing L- and X-type ligands that phosphine ligands are 
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more helpful compared to NHC ligands and Cl- group dramatically accelerates reaction rates. 
 
Figure 1.12. Proposed mechanism of RuAAC of (A) whole catalytic cycle and (B) possible orientation 
of azide and alkyne coordination. 
 
Polymer chemistry gets benefits from methodological studies in preparation of 1,5-disubstituted 
triazoles. RuAAC produces 1,5-isomer structures, different from corresponding CuAAC products, 
eliciting various polymer structures. Building blocks such as two terminal alkynes and two azides could 
form triazoles under elevated temperatures. Hyperbranched structures by cross coupling are also 
reported, but loading different cargoes in polymer is still at the initial stage (Figure 1.13).96-98 RuAAC 
also promotes vigorous investigations in pharmacophores based on target-oriented and diversity-
oriented approaches. But in comparison with CuAAC, harsh conditions (e.g., temperature, aprotic 




Figure 1.13. Examples of polymerization via RuAAC. 
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Covalent Conjugation of Small-Molecule Adjuvants to Nanoparticles Induces Robust Cytotoxic 
T Cell Responses via DC Activation 
 
2.1. Abstract 
Specific recognitions of pathogen associated molecular patterns by Toll-like receptors (TLRs) initiate 
dendritic cell (DC) activation, which is critical for coordinating innate and adaptive immune responses. 
Imidazoquinolines as small-molecule TLR7 agonists often suffer from prompt dissemination and short 
half-life in the bloodstream, preventing their localization to the corresponding receptors and effective 
DC activation. We postulated that covalent incorporation of imidazoquinoline moieties onto the surface 
of biocompatible nanoparticles (∼30 nm size) would enhance their chemical stability, cellular uptake 
efficiency, and adjuvanticity. The fully synthetic adjuvant-nanocomplexes led to successful DC 
activation at lower nanomolar doses compared with free small molecule agonists. Once a model antigen 
such as ovalbumin was used for immunization, we found that the nanocomplexes promoted an 
unusually strong cytotoxic T lymphocyte response, revealing their unique immunostimulatory capacity 
benefiting from multivalency and efficient transport to endosomal TLR7. This chapter is reproduced 




Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs), which coordinate between 
the innate and adaptive immune systems.1 They are specialized to engulf and process antigens and 
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subsequently present epitopes to elicit robust immune responses.2−4 APCs express various types of 
pattern recognition receptors including lectins or TLRs to distinguish between self- and non-self-
structures. Recognition of pathogen associated molecular patterns (PAMPs) by TLRs generally induces 
DC activation.5−7 Activated DCs present foreign epitopes of antigens onto major histocompatibility 
complexes (MHCs), and increase the expression of costimulatory molecules (CD80, CD86) to help 
cognate interaction with T cell receptor (TCR). The expression of chemokine receptor CCR7 leads DCs 
to migrate into lymph nodes, where naiv̈e T cells are transformed into functional T lymphocytes 
including cytotoxic T lymphocytes (CTLs).8,9 
TLR7, located within endosomal compartment, is a promising adjuvant target site for DC-mediated 
immunization. It recognizes nucleotide-derived compounds, including single-stranded RNA or low-
molecular-weight imidazoquinoline derivatives, such as R837 (imiquimod) and R848 (resiquimod).5,8,10 
Yet, promotion of robust CTL responses by small molecule adjuvants is highly challenging due to their 
prompt dissemination through diffusion.8,11−13 To overcome these hurdles, polymeric or inorganic 
nanoparticles (NPs) encapsulating imidazoquinolines have been introduced to enhance stability and 
biodistribution of TLR7 agonists, consequently improving DC activation efficiency.14−17 Here, we 
describe the first synthetic approach for preparing covalently linked imidazoquinoline-nanoconjugates 
for inducing robust CTL responses (Figure 2.1). Our design can entirely avoid the potential time-based 
release of small-molecule agonists from the noncovalently functionalized nanocarriers through the 
interactions between cell membranes and engineered NPs. However, the challenges associated with our 
approach are twofold. First, the design of nanocomplexes requires multistep reactions to achieve a 
molecularly well-defined structure. Second, the synthetic nanocomplexes should effectively initiate 
TLR-mediated DC activation and subsequently induce T cell immunity. To validate our working 
hypothesis, we designed alkyne-functionalized imidazoquinoline derivatives and covalently conjugated 
them with biocompatible NPs to examine their role in DC activation and generation of CTL response. 
 
Figure 2.1. General attributes of Adjuvant-NPs in inducing DC activation and a robust CTL response. 
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2.3. Results and discussion 
Although live-attenuated vaccines can elicit long-term immunity, they have a potential risk of infection, 
and are practically not suitable vaccine candidates against pathogens such as influenza, HIV, or Ebola 
virus.18 In contrast, subunit vaccines provide superior safety profiles and allow tunable design at the 
molecular level to elicit predictable immune responses. However, they are short-lived and poorly 
immunogenic. Thus, immunostimulatory adjuvants are required to generate potent T cell immunity.8,18 
The advent of engineered nanocomplexes loaded with imidazoquinoline analogues opens up new 
opportunities to effectively target TLR7, yet investigations have been established on the basis of 
noncovalent encapsulation chemistry. Although CpG oligodeoxynucleotide-NP complexes have been 
previously demonstrated,19,20 NPs covalently incorporating the small-molecule cognate ligands without 
repeating monomer units have not been reported so far. 
To synthesize well-defined molecular adjuvant-nanocomplexes, we designed and prepared an 
imidazoquinoline analogue (Adjuvant 1) with a terminal alkyne moiety to couple with azide coated iron 
oxide NPs (see Figure 2.2a). Adjuvant 2 was synthesized from 2,4-quinolinediol as previously described 
by the David group.21−24 Based on the previous structure−activity relationship studies,21,25−28 n-butyl 
group was introduced at C-2 position to increase TLR7 agonistic potency. Further, an alkyne 
functionality as a versatile anchor was placed at N-1 position for next-stage chemical reactions, since 
the site modification does not significantly compromise agonistic potency. Molecular structure of TLR7 
agonist, Adjuvant 1, was confirmed by 1H and 13C nuclear magnetic resonance (NMR) spectra (Figure 
2.2b and c). As a conjugation platform displaying multivalency, water-soluble and surface-engineered 
iron oxide NPs were selected because of their biocompatibility, facile surface modification, 
monodisperse size, biomolecule-free structure, and enhanced stability. In addition, they can be 
potentially applied as multifunctional agents for diagnostic/therapeutic purposes (e.g., magnetic 
resonance imaging (MRI) or photothermal therapy).29−34 Biocompatible NPs with monodisperse size 
ranges of ∼30 nm can be used as nanocarriers in vivo, which are optimal for internalization by 
immature DCs by facilitating endolysosomal pathway, and can be trafficked into the draining lymph 
nodes, thereby enhancing their adjuvanticity.11,20,35−38 Amine-surface-modified iron oxide NPs (Amine-
NPs) were then reacted with Spacer 3 with an activated ester moiety, to afford Azide-NPs, since azido 
functionality can be readily installed and is highly orthogonal and versatile for further transformations. 
Finally, Adjuvant 1 was conjugated by CuI-catalyzed Huisgen 1,3-dipolar cycloaddition reaction, and 






Figure 2.2. Synthetic scheme of Adjuvant-NPs (i) HBTU, TEA, DCM, (ii) CuSO4·5H2O, sodium 
ascorbate, DMF, (iii) 0.1 M Tris buffer (pH 6), and (iv) diluted hydrogen chloride solution. (b,c) 1H and 
13C NMR spectra (MeOD) of Adjuvant 1. 
 
Core and hydrodynamic sizes of the synthetic nanocomplexes were determined by transmission electron 
microscopy (TEM) and dynamic light scattering (DLS) analyses, respectively (Figure 2.3a and b). TEM 
imaging revealed spherical and monodisperse particles with ∼11 nm core diameters of Adjuvant-NPs 
without any signs of particle aggregation, even after multistep chemical modifications. DLS data 
analysis showed an effective diameter of 31.6 nm and a narrow size distribution with polydispersity 
index (PDI) = 0.258. Previously NPs having ∼30 nm size were demonstrated to be efficiently taken 
up by DCs.19,20 Moreover, we carried out spectroscopic studies to examine the effectiveness of 
imidazoquinoline conjugation. UV−vis spectrum of Adjuvant-NPs showed distinct imidazoquinoline 
peaks at about 225, 246, and 321 nm with slight peak shifts (Figure 2.3c). To quantify the loading level, 
a fluorescence assay was conducted (Figure 2.3d), since iron oxide NPs are weakly fluorescent. NHS-
fluorescein is an amine reactive fluorescent probe bearing an activated ester moiety, thus, fluorophores 
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can be appended to Adjuvant-NPs to generate Fluorescein-Adjuvant-NPs. Based on the standard curve 
of NHS-fluorescein and iron concentration of NPs, the loading amount of imidazoquinolines in 
Adjuvant-NPs was estimated to be 0.139 μmol/[mg Fe] (Figure 2.12 and 2.13). 
 
 
Figure 2.3. Characterization of Adjuvant-NPs. (a) TEM image of Adjuvant-NPs, (b) DLS analysis, (c) 











Further, we evaluated DC activation efficacies by using synthetic TLR7 agonists. Adjuvant-NPs or free 
Adjuvant 1′ were intraperitoneally injected into mice, and their DCs were harvested 18 h later. DC 
activation markers including CD80, CD86, MHC I, and CCR7 were stained with phycoerythrin (PE)-
conjugated antibodies and analyzed by flow cytometry. R848,10 Adjuvant-NPs, or Adjuvant 1′ 
effectively increased the expression levels of the markers (Figure 2.4-2.7). Highly water-soluble 
Adjuvant 1′ acted as an effective stimulant of DC activation at 115.6 nmol or even at a concentration 
as low as 69.4 nmol (Figure 2.5). Amine-NPs showed weak self-adjuvant effect (Figure 2.7). 
Remarkably, 13.9 nmol of Adjuvant-NPs (concentration in loading levels of cognate ligands) and 115.6 
nmol of free Adjuvant 1′ induced comparable immunostimulatory activities. This is attributed to the 
enhanced avidity as well as effective internalization of the nanocomplexes to the endosomal TLR7 of 
DCs. IL-12p40 is known as one of important pro-inflammatory cytokines secreted from activated DCs 
to educate naiv̈e CD8+ T cells.39 The secreted IL-12p40 levels of the Adjuvant-NP treated group were 
significantly higher than those of groups that were treated with PBS or Amine-NPs (Figure 2.8a). 
Adjuvant 1′ also induced the production of the secreted IL-12p40 at an almost identical level. To 
directly detect the antigen-specific CD8+ T cell response, we carried out MHC I tetramer assays and 
observed increased populations of OT-1 peptide-specific CD8+ T cells in the groups treated with 
Adjuvant 1′ or Adjuvant-NPs compared to those of Amine-NPs (Figure 2.8b). These data suggested 
that Adjuvant-NPs induce efficient DC activation leading to the effective presentation of antigenic 




Figure 2.4. Adjuvant effects on in vivo DC activation: (a) flow cytometry analyses, and (b,c) the mean 
fluorescence intensity (MFI) levels of DC activation markers (CD80, CD86, CCR7, and MHC I). The 








Figure 2.5. DC activation tests at various concentration of Adjuvant 1′.  
 




Figure 2.7. DC activation tests at various concentration of Amine-NPs. 
 
Figure 2.8. (a) IL-12p40 secretion of Adjuvant-NPs in DCs. Samples were analyzed by ELISA after 48 
hours culture. The P values < 0.001(***) were considered significant. (b) Flow cytometry analyses of 
OT-1 peptide specific T cell receptor expressing CD8+ T cells. 
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Since TLR7 is expressed inside endosomal compartments of DCs, effective delivery of antigens and 
adjuvants into DCs is indispensable for their proper maturation and subsequent immune response. 
However, free small molecules hardly localize to TLRs, thus, they require effective delivery vehicles. 
To examine cellular internalization of the nanocomplexes and their appropriate localization in DCs, we 
prepared Fluorescein-Adjuvant-NPs as probes (see Experimental) and studied their uptake using 
confocal fluorescence microscopy (Figure 2.9a). The complexes were cultured with immature DCs in 
vitro in the presence of ovalbumin (OVA) as a model antigen. After 18 h, the cells were fixed, and the 
nuclei and low pH endosomes were stained with DAPI and LysoTracker, respectively. Fluorescent 
confocal cell images clearly demonstrated that Fluorescein-Adjuvant-NPs were localized within 
endosomes thanks to their suitable particle size (∼30 nm) (Figure 2.9b and 2.10),19,20 which can assist 
















Figure 2.9. (a,b) Fluorescence imaging studies to examine the internalization of Fluorescein-Adjuvant-
NPs in DCs. Samples were characterized by confocal fluorescent microscopy. 
 
 
Figure 2.10. Z-stacking 3D Fluorescence images to examine the internalization of Fluorescein-
Adjuvant-NPs in DCs. 
 
The efficient DC activation and nanocomplex internalization prompted us to test whether these mature 
DCs can elicit sufficient cytotoxic CD8+ T cell responses. We performed an in vivo CTL assay based 
on the carboxyfluorescein diacetate succinimidyl ester (CFSE) assay to monitor OVA-specific T cell 
proliferation.40,41 Mice were intraperitoneally immunized with 25 μg of OVA protein as an antigen in 
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the presence of PBS, R848, Amine-NPs, or Adjuvant-NPs as TLR7 agonists. Groups of mice were 
primarily immunized for 2 weeks, and additionally boosted for 1 week. After immunization, mice were 
intravenously injected with 50:50 mixtures of OT-1 peptidepulsed (CFSEhi) and unpulsed (CFSElow) 
syngeneic splenocytes to evaluate OVA-specific CTL activity. The population of OT-1 peptide pulsed 
target cells was analyzed by flow cytometry. It is speculated that if OT-1 specific T cells are effectively 
stimulated by matured DCs with OVA protein and adjuvants, the percentage of OT-1 peptide-pulsed 
(CFSEhi) syngeneic splenocytes would be lysed and their population decreased because of T cell 
cytotoxicity (Figure 2.11a). Remarkably, injection of Adjuvant-NPs with 27.8 nmol of adjuvant 
together with OVA protein caused 84% target cell lysis. In contrast, small-molecule R848 (28.5 or 
142.5 nmol) or Amine-NPs showed negligible to poor (0−25%) cytotoxic responses (Figure 2.11b). It 
is speculated that superior CD8+ T cell efficacy of Adjuvant-NPs at low doses of imidazoquinoline 
moiety is associated with the enhanced avidity of fully synthesized multivalent Adjuvant-NPs and 
effective DC internalization. 
 
Figure 2.11. In vivo CTL assay on splenocytes. (a) Percentages of OT-1 peptide unpulsed CFSElow (left) 
and that of pulsed CFSEhigh (right) were analyzed by flow cytometry. Each group was stimulated with 
indicated adjuvants: Sample A: R848 10 μg, 28.5 nmol, sample B: R 848 50 μg, 142.5 nmol, sample C: 
amine-NPs 100 μg Fe, sample D: amine NPs 200 μg Fe, sample E: Adjuvant-NPs (100 μg Fe, 13.9 
nmol of imidazoquinoline), sample F: Adjuvant-NPs (200 μg Fe, 27.8 nmol of imidazoquinoline) along 
with OVA protein. (b) Conversion of the percentages of CFSEhigh based on the negative control of PBS 




We chemically synthesized structurally well-defined molecular adjuvant-nanoparticle conjugates 
through multistep reactions and investigated their potency of immunostimulatory activity. The 
nanocomplexes displaying multiple low-molecular-weight ligands were efficiently internalized by 
immature DCs, and they subsequently enhanced in vivo DC activation by facilitating multivalent 
interactions between imidazoquinoline moieties and endosomal TLR7. In addition, they induced 
increased expression levels of activation markers in the low nanomolar range. Their cellular localization 
was validated by fluorescent labeling of the nanocomplexes. Co-administration of the synthetic 
adjuvant-nanocomplexes and OVA protein elicited unusually robust antigen-specific cytotoxic T cell 
responses. Considering the significant challenges generating cell-mediated immunity via small-
molecule based adjuvant systems, we believe that our synthetic approach can provide a versatile 




N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 98%), 4-
pentynoic acid (95%), copper(II) sulfate pentahydrate (98%), (+)-sodium L-ascorbate (98%), and N-
hydroxysuccinimide (NHS, 98%) was purchased from Sigma-Aldrich. Amine-functionalized iron oxide 
(Fe3O4) magnetic nanoparticles (aqueous solution, 5 mg/mL Fe) were supplied by Ocean nanotech. 
Triethylamine (TEA, 99%) was obtained from Alfa Aesar. NHS-fluorescein (5/6-carboxyfluorescein 
succinimidyl ester) was purchased from Thermo Scientific. 
Instruments 
Proton nuclear magnetic resonance and carbon nuclear magnetic resonance spectra were recorded by 
an Agilent 400-MR DD2 and an Agilent VNMRS 600. Low resolution mass spectra were measured by 
a Bruker HCT Basic System with electrospray ionization (ESI) source. High resolution mass spectra 
were measured by an ABI API-3000 ESI mass spectrometer. Fluorescence spectra were measured by 
using an Agilent Cary Eclipse fluorescence spectrophotometer. UV-Vis spectra were recorded by a 
Jasco V-670 spectrometer. Dynamic light scattering (DLS) was measure by a Brookhaven Instrument 





Synthesis of Adjuvant 1 
Adjuvant 221 (400 mg, 1.11 mmol) and TEA (547 μL, 3.89 mmol, 3.5 equiv) were dissolved in DCM 
(80 mL). 4-Pentynoic acid (142 mg, 1.45 mmol, 1.3 equiv) and HBTU (549 mg, 1.45 mmol, 1.3 equiv) 
were added at 0 °C, and the solution left to stir overnight at room temperature. The reaction mixture 
was concentrated in vacuo and the residue was purified by flash column chromatography 
(DCM:MeOH:NH4OH = 9.5:0.5:0.1) to yield the title compound as a clear oil (261 mg, 53%). 1H NMR 
(400 MHz, MeOD) δH 0.92 (t, J 7.4 Hz, 3H), 1.42 (dt, J 14.7, 7.4 Hz, 2H), 1.77 (dt, J 15.4, 7.6 Hz, 2H), 
2.20 (t, J 2.6 Hz, 1H), 2.34−2.49 (m, 4H), 4.33 (s, 2H), 5.82 (s, 2H), 7.00 (d, J 8.1 Hz, 2H), 7.09 (m, 
1H), 7.27 (d, J 8.1 Hz, 2H), 7.41 (m, 1H), 7.65 (dd, J 8.3, 0.4 Hz, 1H), 7.78 (d, J 7.8 Hz, 1H), 13C NMR 
(150 MHz, MeOD) δC 14.1, 15.7, 23.4, 27.8, 30.7, 35.9, 43.6, 49.5, 70.3, 83.5, 115.7, 121.5, 123.4, 
126.2, 126.7, 126.9 128.5 129.4 135.4, 136.0, 139.8, 144.8, 152.5, 156.0, 173.8., HRMS (ESI): Calcd 
for C27H30N5O+ [M + H]+: 440.2445, found 440.2445. 
Synthesis of Azido-NPs 
Spacer 342 (30 mg, 116 μmol) dissolved in DMF was added to the Amine-NPs (1.5 mg Fe). Mixture 
was stirred at room temperature for a day, then dialyzed in DI water three times to remove 
nonconjugated molecules in excess. 
Synthesis of Adjuvant-NPs 
Adjuvant 1 (2.55 mg, 5.80 μmol, 15 equiv) dissolved in DMF, CuSO4·6H2O (1.45 mg, 5.80 μmol, 15 
equiv), and (+)-sodium L-ascorbate (1.15 mg, 5.80 μmol, 15 equiv) was added to Azide-NPs and stirred 
at room temperature for a day. The reaction mixture was dialyzed in DI water two times and then treated 
with 0.1 M Tris buffer (pH 6) two times to form the ammonium salt of imidazoquinoline moiety. 
Solution was filtered through 0.2 μm pore size filter and concentrated to 3 mg/mL Fe, and then dissolved 
in autoclaved PBS buffer by using centrifugal filter (3000 rpm, 12 min). 
Synthesis of Fluorescein-Adjuvant-NPs 
For the fluorescence analysis and confocal analysis of DC uptake with nanoparticle, NHS-fluorescein 
was utilized to append fluorescein to Adjuvant-NPs (Figure 2.12). To a solution of Adjuvant-NPs in 
PBS buffer was added NHS-fluorescein (0.92 mg, 1.94 µmol, 5 equiv to Amine-NPs (1.5 mg Fe)) and 
stirred for 1 day at room temperature. NHS-fluorescein in excess was removed by DI water dialysis (for 
3 times) and the solution was centrifuged (3000 rpm, 12 min, for 3 times). Then Fluorescein-Adjuvant-




Figure 2.12. Synthesis of Fluorescein-Adjuvant-NPs. 
 
Calculation of loading amount of imidazoquinolines on NPs by fluorescence assay 
 
NHS-fluorescein has specific wavelength of excitation (494 nm) and emission (518 nm). Standard curve 
was generated by plotting emission absorbance against concentration (Figure 2.13). Azide-NPs showed 
negligible absorbance level in the range of 500-600 nm. Serial dilutions were done to produce 0.001 
mg Fe/mL solution, which gave a y value of 176.4. Based on the calibration curve, the concentration of 
imidazoquinoline moiety was evaluated as 0.139 µM. Thus, the loading level of TLR 7 agonists on NPs 
is 0.139 µmol/[mg Fe]. 
 
 







Female C57BL/6 mice were purchased from Taconic. All mice were maintained under specific 
pathogen-free (SFP) conditions and used at 6-8 weeks with Institutional Animal Care and Use 
guidelines. The Institutional Animal Care and Use Committee of the Ulsan National Institute of Science 
and Technology (UNISTIACUC) approved the in vivo animal experiments conducted in this study. 
DC activation 
Mice were injected intraperitoneally (I.P.) with R848 (InvivoGen, San Diego, CA), Adjuvant 1’, Amine-
NPs, Adjuvant-NPs, or PBS for in vivo DC activation. Mice were sacrificed after 18 hours of injection. 
Whole splenocytes were harvested and stained with CD11c FITC. Cells were subsequently stained with 
CD80 PE, CD86 PE, MHC II PE, CCR7 PE and isotypes control (supplied by BioLegend). Activation 
of CD11c+ DC were measured by BD FACS Fortessa and analyzed by FlowJo software (TreeStar). 
DC isolation 
Spleens were harvested from mice to HBSS buffer (GIBCO), then, ballooning with 400 Mandl U/ml 
collagenase D (Roche) and tear them into small pieces by 25G needle and 3 ml syringe. CD11c+ cells 
were positively enriched with magnetic activated cell sorting (MACS, Miltenyi Biotech). Sorted T cells 
showed >98 % purity, as detected by flow cytometry. All flow cytometry data were acquired by BD 
FACS Fortessa and analyzed by FlowJo software (TreeStar). 
Confocal microscopic imaging of DCs 
1 × 106 Cells/ml of immature DCs were isolated and incubated on coverslip in 24 wells plate with 
indicated PBS or NP 7 with 5 µg of OVA protein as a model antigen onto cover slip for 18 hours at 
37 °C. Matured DCs were treated with 50 nM of lysotracker (Thermo-Fisher scientific) to stain the 
lysosome with red fluorescence for last 2 hours. Nucleus was stained with DAPI and images of green 








In vivo cytotoxic T lymphocyte (CTL) assay 
For in vivo CTL assay, mice were immunized with 50 µg of OVA protein with indicated adjuvant 
intraperitoneally, list indicated adjuvants. After 7 days, mice were re-immunized to boost immune 
responses. Then, mice were intravenously injected with 1:1 mixtures of OT-I peptide-pulsed (5 µM 
CFSE-labeled, CFSEhi) and unpulsed (0.5 µM CFSE-labeled, CFSElow) syngeneic splenocytes (7×106 
of each). 18 Hours later, single cells were harvested form lymph nodes and spleens from each mouse. 
OT-I specific CTL activity was evaluated by flow cytometry. We repeated in vivo CTL assay three times 
and three mice were used in each group (total 9 mice/experimental set). 
MHC I tetramer assay 
To investigate OVA epitope (OT-I peptide) specificity induced by adjuvant-NPs vaccination, immunized 
mice as CTL experiment were sacrificed and single homogenized splenocytes were harvested. Cells 
were meshed with 70 µm pore strainer, then, re-stimulated with OT-I peptide (1 µM) in 96 well plate 
(5× 105 cells/ 200 µl) at humidified incubator for 4 days. OT-I peptide specific T cell receptor expressing 
T cells were stained with PE-conjugated MHC I tetramer (Glycotope), then analyzed by flow cytometry. 
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Transition-metal-catalyzed or metal-free azide−alkyne cycloadditions are methods to access 1,4- or 1,5-
disubstituted 1,2,3-triazoles. Although the copper-catalyzed cycloaddition to access 1,4-disubstituted 
products has been applied to biomolecular reaction systems, the azide−alkyne cycloaddition to access 
the complementary 1,5-regioisomers under aqueous and ambient conditions remains a challenge due to 
limited substrate scope or moisture-/air-sensitive catalysts. Herein, we report a method to access 1,5-
disubstituted 1,2,3-triazoles using a Cp2Ni/Xantphos catalytic system. The reaction proceeds both in 
water and organic solvents at room temperature. This protocol is simple and scalable with a broad 
substrate scope including both aliphatic and aromatic substrates. Moreover, triazoles attached with 
carbohydrates or amino acids are prepared via this cycloaddition. This chapter is reproduced from J. 




Switching the regiochemical outcome is one of the issues in modular synthetic approaches involving 
carbon−heteroatom bond-forming processes.1-3 It is important to impart a high level of regiocontrol to 
the Huisgen 1,3-dipolar cycloaddition, which assembles two molecular bricks, an organic azide and an 
alkyne, with ideal atom economy.1-6 The thermal cycloaddition exhibits high activation barriers and 
poor regioselectivity at elevated temperatures. Rapid and regioselective formation of 1,4-disubstituted 
products has been accomplished by the copper-catalyzed azide−alkyne cycloaddition (CuAAC), since 
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the first reports by the groups of Sharpless and Meldal.7,8 The main features of this utilized click 
chemistry include operational simplicity, mild conditions, a broad substrate scope, bioorthogonality, 
favorable kinetics, and high yields. The transformation proceeds not only in organic solvents but also 
in aqueous media at room temperature. As the 1,4-disubstituted 1,2,3-triazole scaffold is chemically 
stable, aromatic, and pharmacologically important, the CuAAC reactions have flourished in medicinal 
chemistry, materials science, and chemical biology.1-6, 9-15 
Synthetic pathways complementary to the CuAAC have been developed to access 1,5-disubstituted 
1,2,3-triazoles. As illustrated in Scheme 3.1a, a metal acetylide reacts with an organic azide to afford a 
4-metalated triazole.16-19 Subsequent aqueous quenching can lead to product formation.16,18,19 Kwok et 
al. introduced a metal-free synthetic route to furnish 1,5-diaryl-1,2,3-triazoles (Scheme 3.1b).20 Fokin, 
Jia, and co-workers reported the ruthenium-catalyzed azide−alkyne cycloaddition (RuAAC), obtaining 
a range of products under inert atmosphere (Scheme 3.1c).21-23 However, the RuAAC reactions using 
[Cp*RuCl] complexes are typically sensitive to water and air, and proceed at elevated temperatures.24,25 
These conditions limit their application in biochemical research. The development of methods 
compatible with aqueous and ambient conditions remains a challenge.26-30 Herein we report a strategy 
to access 1,5-disubstituted 1,2,3-triazoles by the nickel-catalysis. Functionalization of carbohydrates 
and amino acids has been also accomplished via this developed nickel-catalyzed azide−alkyne 




Scheme 3.1. Synthesis of 1,5-disubstituted 1,2,3-triazoles. 
 
3.3. Results and discussion 
We initiated our investigation of the NiAAC by treating two simple substrates, benzyl azide 1a and 
phenylacetylene 2a, with a catalytic amount of nickel precatalyst at room temperature without effort to 
exclude air and moisture (Table 3.1). All reagents including precatalysts, ligands, and solvents were 
used as-received from standard suppliers with no extra purification steps. After extensive screening of 
precatalysts, ligands, and additives (Tables 3.2-3.5), the reaction conditions were optimized to achieve 
high yield and excellent regioselectivity. Under the standard conditions, the desired 1,5-disubstituted 
triazole 3aa was isolated in 94% yield with only 6% of 4aa (entry 1). The regioisomers were separated 
by flash column chromatography. In the absence of the nickelocene (Cp2Ni) precatalyst or the bidentate 
Xantphos ligand, the 1,2,3-triazole core was not formed (entries 2−5). Control experiments showed 
nickel precatalysts lacking the Cp ligands or other metallocene complexes were ineffective (entries 2−4, 
see Tables 3.2 and 3.3). Yet, more sterically demanding Cp-based complexes resulted in comparable or 
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unsatisfactory results (Table 3.3). Replacement of Xantphos with other P- or N-ligands caused 
diminished or no catalytic activity (Table 3.4). The use of DPEphos as the ligand, which has a similar 
structure to Xantphos (Table 3.1, entry 6, see also Scheme 3.1), furnished 3aa in 76% yield. Geometrical 
constraints such as the rigidity of the backbone and a wide bite angle may play a critical role in 
determining the reactivity of the NiAAC.31,32 Among the mild bases screened, Cs2CO3 was optimal 
(Table 3.5). The reaction was less effective when the precatalyst/ligand loading was reduced (Table 3.1, 
entry 8). Elevated temperatures (entries 9 and 10) lowered the reaction yield and regioselectivity, 
presumably due to catalyst decomposition or the involvement of the thermal pathway. A shortened 
reaction time (1.5 h) did not significantly affect the yield (entry 11). The reaction proceeded well in 
other solvents including DMF, DCM, and even water (entries 12−14) with similar yields and 
regioselectivity. This NiAAC reaction is highly compatible with water as the sole solvent and can be 
carried out under air at room temperature. 
 




Table 3.2. Nickel catalyst screening.[a] 
 








Table 3.5. Base/additive screening.[a] 
 
With the optimized conditions based on the Cp2Ni/Xantphos catalytic system in hand, the substrate 
scope and generality of this NiAAC reaction were investigated under aqueous conditions at room 
temperature (Scheme 3.2). Owing to the poor solubilities of the precatalyst, ligand, and substrates in 
water, reactions were conducted as aqueous suspensions. Reactions of various azides (1b and 1e−1k) 
produced the corresponding 1,5-disubstituted triazoles in moderate to excellent isolated yields (63−95%) 
with high regioselectivity ranging from 11.4:1 to >99:1 for 3/4. However, regioselectivity was 
significantly decreased when phenyl azide 1c (3.2:1 ratio) or 1-azidoadamantane 1d was used (4.5:1 
ratio). This can be attributed to the steric congestion between the substrates and catalytic Ni species 
containing Cp and Xantphos ligands. Various functional groups of 1, including fluorinated arenes and 
fused cyclic moieties, were compatible with the reaction conditions. The hydroxyl and ester functional 














Regarding the organic alkyne partner 2, aliphatic and aromatic alkynes with diverse functional groups, 
including methoxy-, amine-, nitro-, chloro-, and methyl moieties, were well-tolerated. Yet, ortho-OMe-
substituted alkyne 2c showed no reactivity owing to the steric effect. The NiAAC reaction is favored 
with less-sterically hindered meta- and para-substituted substrates 2d and 2e. It was reported RuAAC 
reactions are significantly affected by steric factor of alkynes.22 However, the contribution of electronic 
factor cannot be ruled out (3ab, 3ag, and 3ah). The cycloaddition of the electronically unbiased internal 
alkyne 2l afforded 3al in 88% yield. Unsymmetrical internal alkynes 2m and 2n also participated in the 
NiAAC to give fully substituted triazoles,21-25,33 albeit with poor regioselectivity. Regiochemical 
assignments were confirmed by 2D NMR (Figure 3.1),7,8,25,33 assisted by the 13C chemical shifts of the 
triazole CH.34 In addition, single-crystal X-ray crystallographic analyses determined structures of the 
1,5-disubstituted triazoles 3ja and 3ah (Table 3.6 and 3.7). 
To expand the repertoire of the NiAAC, this developed click reaction was explored to include 
biomolecules such as carbohydrates and amino acids. In particular, glycoconjugates feature unparalleled 
branched structures, compared with oligopeptides or oligonucleotides, with diverse configurations and 
glycosidic linkages.9,35-39 Their effective functionalization has been achieved by producing non-natural 
glycoconjugates and amino acid derivatives (Scheme 3.3). Both O- and N-linked sugars were well-
tolerated in this NiAAC (3la−3oa). In addition, the cycloaddition reaction could be scaled up to a 1 g 
of 1m with an increased reaction yield of 82% (3ma). Maltose azide 1p, a disaccharide moiety, could 
be incorporated affording the cycloaddition product in 74% yield, albeit in DCM, due to the solubility 
problem. Finally, both carbohydrate 1o and amino acid 2o were subjected to the NiAAC, and non-
natural glyco-amino acid 3oo was successfully prepared in 65% yield, presenting the potential of 
biomolecule conjugation. However, the attempted NiAAC reactions with unprotected sugars were not 












Scheme 3.3. Expanded scope with respect to non-natural carbohydrates and amino acids.a 
 
 





Having established the utility of the Cp2Ni/Xantphos catalytic system for azide−alkyne cycloaddition, 
we turned our attention to the Ni species that may be present in solution. Literature indicates that 
reaction of Cp2Ni with mono- and bidentate phosphine ligands may, in some cases, give CpNi(P-
ligand)2 and Ni(P-ligand)4 complexes.40-43 The formal one-electron reduction steps of the Ni center 
(from NiII to NiI to Ni0) upon coordination of the phosphine ligands may be explained by successive 
dissociation of Cp• radicals.44,45 Indeed, analysis of the reaction between Cp2Ni and Xantphos by EPR 
spectroscopy and mass spectrometry gave results consistent with the presence of CpNi(Xantphos) and 
Ni(Xantphos)2 (see the Experimental). The EPR spectrum of the reaction mixture shows a triplet 
resonance signal centered at g = 2.088 with a hyperfine splitting constant of a = 104 G (Figure 3.2), as 
expected for a paramagnetic NiI center (S = 1/2) coupled to two 31P nuclei.40,44−47 Moreover, these 
parameters are similar to those reported for related Ni complexes, such as CpNi-(dppe).40,44 
Next, the high-resolution ESI mass spectrum (Figure 3.3) of the reaction mixture exhibits the most-
abundant peak at m/z 701.1671, which is attributed to [CpNi(Xantphos)]+. Measured and calculated 
isotope distributions were well-matched. In addition, a peak at m/z 630.1638 is assigned to 
[Ni(Xantphos)2+2Na]2+.41-43 Because the reactions in this study were performed under air, it may seem 
likely that CpNi(Xantphos), at least in part, undergoes oxidization, giving rise to the corresponding NiII 
complex [CpNi(Xantphos)]+ detected in positive ESI mode. Together, these findings agree with the 
reaction sequences (i) Cp2Ni → CpNi(Xantphos) → Ni(Xantphos)2 and (ii) CpNi(Xantphos) → 
CpNi(Xantphos)+. More detailed studies are needed, however, to confirm the presence of these species 
and to determine which ones are involved in the NiAAC reaction.  
On the basis of literature reports48-50 and our experimental results, a reaction mechanism is suggested 
as shown in Scheme 3.5. Alkyne and azide coordinate to Ni, forming intermediate A, while the spectator 
ligands (Cp and/or Xantphos) may change their bonding modes to accommodate the new ligands. 
Because both internal and terminal alkynes participate in this cycloaddition (vide supra, see Scheme 
3.2), the formation of a nickel−acetylide species is excluded. The C−N bond formation between alkyne 
and azide giving complex B determines 1,5-regioselectivity, analogous to the RuAAC pathway.22 
Subsequent reductive elimination leads to the formation of cyclized target product 3, while regenerating 






Scheme 3.5. Tentative reaction mechanism of the NiAAC. 
 
3.4. Conclusion 
In summary, we developed the nickel-catalyzed azide−alkyne cycloaddition to access 1,5-disubstituted 
1,2,3-triazoles from available substrates and inexpensive reagents at room temperature. The Cp2Ni 
precatalyst and Xantphos ligand were critical to accomplish the catalytic manifold, insensitive to 
molecular oxygen and water. This methodology exhibits a broad substrate scope, good functional group 
tolerance, high yields, and high regioselectivity, complementing the classical copper-catalyzed click 
chemistry that produces 1,4-disubstituted 1,2,3-triazoles. The synthetic utility of this nickel-catalyzed 
pathway has been highlighted by the functionalization of carbohydrates and amino acids. Further 




Reactions were monitored by thin-layer chromatography (TLC) using Merck silica gel 60F254 glass 
plate with 0.25 mm thickness. The glass plates were visualized by a ultra-violet lamp (254 nm) and 
stained with potassium permanganate solution. Flash column chromatography was carried out using 
Merck silica gel 60 (size range: 0.040–0.063 mm). 1H, 13C, and 19F NMR spectra were recorded on a 
Bruker Avance III HD (400 MHz for proton, 100 MHz for carbon) or an Agilent VNMRS 600 (600 
MHz for proton, 150 MHz for carbon). Chemical shifts are given on the δ-scale in ppm, and residual 
solvent peaks were used as internal standards. High-resolution mass spectrometry (HRMS) data were 
51 
 
measured on a Thermo Scientific Q Exactive Plus Hybrid Quadrupole-Orbitrap mass spectrometer. 
Single-crystal X-ray analysis was conducted by monochromatic synchrotron X-rays (λ = 0.66 Å, 6D 
UNIST-PAL beamline) with a Rayonix MX225-HS detector. Electron paramagnetic resonance (EPR) 
spectra were obtained on a Bruker EMXplus 9.5/12 spectrometer. 
Experimental procedures 
(CAUTION!) organic and inorganic azides are potentially explosive and toxic. In particular, the use of 
metal spatula for weighing sodium azide should be avoided. 
Synthesis of organic azides: (1b, 1e, 1j),51 (1a, 1g),52 1f,53 1h54 
Organic bromide (1.0 equiv) was treated with sodium azide (1.5 equiv) in DMSO or a mixture of 1:3 
water/acetone solution. Solution was stirred at rt or 80 ºC. After 12–24 h, the reaction mixture was 
diluted with D.I. water, and then extracted with diethyl ether 3 times. The combined organic layer was 
washed with water and brine, dried over sodium sulfate, and then concentrated in vacuo. The 
corresponding product was purified by flash column chromatography. 
Preparation of organic azides 
Methyl 6-azidohexanoate 1i,55 1-azidomethylpyrene 1k,56 2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-
D-glucopyranosyl azide 1l,57 2-acetylamido-2-deoxyl-β-D-glucopyranosyl azide 1l',58 2,3,4,6-tetra-O-
acetyl-β-D-glucopyranosyl azide 1m,59 β-D-glucopyranosyl azide 1m',60 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl azide 1n,61 2′-azidoethyl-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 1o,62 and 
2,3,6,2′,3′,4′,6′-hepta-O-acetyl-β-maltosyl azide 1p63 were synthesized according to previously reported 
methods. Azidobenzene solution 1c (0.5 M in tert-butyl methyl ether) and 1-azidoadamantane 1d were 





Scheme 3.6. Preparation of organic azides. 
Preparation of alkynes 
N-Boc-4-ethynyl-L-phenylalanine methyl ester 2o64 was synthesized according to previously reported 
method. Other alkynes were purchased from standard suppliers (Sigma-Aldrich, TCI, and Alfa Aesar). 
General Procedure for the NiAAC 
To a mixture of nickelocene (10 or 20 mol%) and Xantphos ligand (10 or 20 mol%) in water or organic 
solvent (2.0 mL), alkyne 2 (1.2 equiv, 0.46 mmol) and cesium carbonate (1.0 equiv, 0.38 mmol) were 
added at 0 ºC. Then, organic azide 1 (1.0 equiv, 0.38 mmol) was added and the reaction mixture was 
stirred at rt. After 1.5–17 h, the suspension was diluted with DCM, washed with water, and dried over 





1H NMR spectra of (3aa, 3ba, 3ha, 3al),23 3ca,65 3da,66 3ia,67 (3ae, 3ai),68 3aj,69 3ma,70 and 3am (as a 
regioisomeric mixture)71 are in good agreement with the previously reported literature values. 
1-(1-Adamantyl)-5-phenyl-1H-1,2,3-triazole (3da) 
81% yield, brown solid, 1H NMR (600 MHz, CDCl3) δ 7.47 (s, 1H), 7.42 – 7.35 (m, 
3H), 7.29 – 7.25 (m, 2H), 2.16 (s, 6H), 2.05 (s, 3H), 1.61 (d, J = 12.3 Hz, 3H), 1.55 (d, 
J = 11.9 Hz, 3H), 13C NMR (100 MHz, CDCl3) δ 136.8, 135.5, 130.5, 130.1, 129.2, 




88% yield, brown solid, 1H NMR (600 MHz, CDCl3) δ 7.62 (s, 1H), 7.46–7.37 (m, 
3H), 7.08 (d, J = 6.5 Hz, 2H), 6.86 (d, J = 7.0 Hz, 4H), 4.52 (t, J = 7.2 Hz, 2H), 
3.14 (t, J = 7.2 Hz, 2H), 13C NMR (150 MHz, CDCl3) δ 162.0 (d, J = 245.3 Hz), 
138.3 (s), 133.0 (s), 132.9 (d, J = 3.3 Hz), 130.3 (d, J = 8.0 Hz), 129.5 (s), 129.0 
(s), 128.8 (s), 127.1 (s), 115.6 (d, J = 21.3 Hz), 49.5 (s), 35.8 (s), 19F NMR (376 MHz, CDCl3) δ -115.75 
– -115.92 (m), HRMS (ESI+) m/z calcd for C16H15FN3 ([M+H]+) 268.1244, found 268.1242. 
 
5-Phenyl-1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazole (3fa) 
87% yield, white solid, 1H NMR (600 MHz, CDCl3) δ 7.73 (s, 1H), 7.52 (d, J = 
8.1 Hz, 2H), 7.46 – 7.38 (m, 3H), 7.23 (d, J = 6.5 Hz, 2H), 7.17 (d, J = 8.0 Hz, 
2H), 5.59 (s, 2H). 13C NMR (150 MHz, CDCl3) δ 139.4 (s), 138.3 (s), 133.3 (s), 
130.4 (q, J = 32.7 Hz), 129.7 (s), 129.1 (s), 128.8 (s), 127.5 (s), 126.6 (s), 125.8 (q, J = 3.7 Hz), 123.8 
(q, J = 272.2 Hz), 51.2 (s), 19F NMR (376 MHz, CDCl3) δ -62.70 (s), HRMS (ESI+) m/z calcd for 
C16H13F3N3 ([M+H]+) 304.1056, found 304.1051. 
 
1-(3,5-Bis(trifluoromethyl)benzyl)-5-phenyl-1H-1,2,3-triazole (3ga) 
84% yield, yellow oil, 1H NMR (600 MHz, CDCl3) δ 7.76 (s, 1H), 7.73 (s, 1H), 7.51 
– 7.41 (m, 5H), 7.21 (d, J = 7.1 Hz, 2H), 5.65 (s, 2H), 13C NMR (100 MHz, CDCl3) 
δ 138.3 (s), 137.7 (s), 133.7 (s), 132.3 (q, J = 33.7 Hz), 130.1 (s), 129.4 (s), 128.9 
(s), 128.0 (d, J = 2.7 Hz), 126.5 (s), 122.9 (q, J = 272.9 Hz), 122.5 (dt, J = 6.9, 3.4 
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Hz), 51.0 (s), 19F NMR (376 MHz, CDCl3) δ -63.04 (s), HRMS (ESI+) m/z calcd for C17H11F6N3Na 
([M+Na]+) 394.0749, found 394.0748. 
 
1-(Naphthalen-2-ylmethyl)-5-phenyl-1H-1,2,3-triazole (3ja) 
92% yield, brown solid, 1H NMR (600 MHz, CDCl3) δ 7.82 – 7.75 (m, 3H), 7.72 – 
7.69 (m, 1H), 7.50 – 7.36 (m, 6H), 7.27 – 7.24 (m, 3H), 5.70 (s, 2H), 13C NMR (100 
MHz, CDCl3) δ 138.3, 133.4, 133.2, 133.1, 133.0, 129.6, 129.1, 129.0, 128.9, 128.0, 
127.8, 127.0, 126.6, 126.5, 126.3, 124.8, 52.0, HRMS (ESI+) m/z calcd for C19H16N3 ([M+H]+) 
286.1338, found 286.1335. 
 
5-Phenyl-1-(pyren-2-ylmethyl)-1H-1,2,3-triazole (3ka) 
63% yield, brown solid, 1H NMR (400 MHz, CDCl3) δ 8.04 (dd, J = 7.6, 3.4 Hz, 
2H), 7.97 (d, J = 9.2 Hz, 1H), 7.93 – 7.82 (m, 5H), 7.70 (s, 1H), 7.28 – 7.22 (m, 
2H), 7.21 – 7.13 (m, 2H), 7.08 (dt, J = 5.9, 2.7 Hz, 2H), 6.13 (s, 2H), 13C NMR 
(100 MHz, CDCl3) δ 138.5, 133.5, 131.3, 131.2, 130.6, 129.6, 129.1, 128.9, 
128.5, 128.3, 128.0, 127.8, 127.3, 127.0, 126.2, 125.7, 125.6, 125.5, 124.9, 124.8, 124.6, 121.8, 50.1, 
HRMS (ESI+) m/z calcd for C25H17N3Na ([M+Na]+) 382.1314, found 382.1314. 
 
1,5-Dibenzyl-1H-1,2,3-triazole (3ab) 
67% yield, yellow solid, 1H NMR (400 MHz, CDCl3) δ 7.38 (s, 1H), 7.27 – 7.16 (m, 
6H), 7.04 – 6.90 (m, 4H), 5.32 (s, 2H), 3.76 (s, 2H), 13C NMR (100 MHz, CDCl3) δ 
136.0, 134.8, 134.4, 129.1, 129.0, 128.5, 128.4, 127.4, 127.3, 52.0, 29.4, HRMS (ESI+) 
m/z calcd for C16H15N3Na ([M+Na]+) 272.1158, found 272.1157. 
 
1-Benzyl-5-(3-methoxyphenyl)-1H-1,2,3-triazole (3ad) 
93% yield, yellow oil, 1H NMR (600 MHz, CDCl3) δ 7.72 (s, 1H), 7.35 – 7.22 (m, 4H), 
7.08 (d, J = 6.6 Hz, 2H), 6.95 (dd, J = 8.3, 2.1 Hz, 1H), 6.84 (d, J = 7.5 Hz, 1H), 6.71 
(s, 1H), 5.54 (s, 2H), 3.68 (s, 3H), 13C NMR (100 MHz, CDCl3) δ 159.8, 138.1, 135.7, 
133.3, 130.1, 128.9, 128.2, 128.1, 127.1, 121.2, 115.4, 114.2, 55.3, 51.9, HRMS (ESI+) 





72% yield, yellow oil, 1H NMR (600 MHz, CDCl3) δ 7.81 (s, 1H), 7.77 (d, J = 8.4 
Hz, 1H), 7.66 – 7.61 (m, 2H), 7.32 – 7.10 (m, 8H), 5.59 (s, 2H), 3.94 (s, 3H), 13C 
NMR (100 MHz, CDCl3) δ 158.8, 138.5, 135.8, 134.8, 133.5, 129.8, 129.0, 128.5, 
128.3, 127.7, 127.3, 126.5, 121.8, 120.1, 105.7, 55.5, 52.0, HRMS (ESI+) m/z 
calcd for C20H18N3O ([M+H]+) 316.1444, found 316.1439. 
 
4-(1-Benzyl-1H-1,2,3-triazol-5-yl)aniline (3ag) 
77% yield, brown oil, 1H NMR (600 MHz, CDCl3) δ 7.64 (s, 1H), 7.29 – 7.22 (m, 
3H), 7.08 (d, J = 6.5 Hz, 2H), 7.00 (d, J = 8.5 Hz, 2H), 6.65 (d, J = 8.5 Hz, 2H), 5.49 
(s, 2H), 3.98 (s, 2H), 13C NMR (100 MHz, CDCl3) δ 147.9, 138.6, 135.9, 132.8, 
130.0, 128.8, 128.0, 127.1, 116.0, 115.0, 51.5, HRMS (ESI+) m/z calcd for C15H15N4 ([M+H]+) 
251.1291, found 251.1291. 
 
1-Benzyl-5-(4-nitrophenyl)-1H-1,2,3-triazole (3ah) 
74% yield, yellow solid, 1H NMR (600 MHz, CDCl3) δ 8.24 (d, J = 8.7 Hz, 2H), 
7.82 (s, 1H), 7.43 (d, J = 8.7 Hz, 2H), 7.32–7.25 (m, 3H), 7.07–7.01 (m, 2H), 5.59 
(s, 2H), 13C NMR (100 MHz, CDCl3) δ 148.3, 136.1, 135.0, 134.2, 133.4, 129.8, 




57% yield, brown solid, 1H NMR (400 MHz, CDCl3) δ 7.49 (s, 1H), 7.35 – 7.27 (m, 
3H), 7.18 – 7.10 (m, 2H), 5.50 (s, 2H), 3.44 (t, J = 6.1 Hz, 2H), 2.52 (t, J = 7.3 Hz, 
2H), 1.75 – 1.63 (m, 4H), 13C NMR (100 MHz, CDCl3) δ 136.7, 135.0, 132.8, 129.1, 







(4-methoxyphenyl)-1H-1,2,3-triazole (3an): an inseparable regioisomeric 1:1 mixture 
32% yield, brown solid, 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.37 (m, 4H), 
7.22 – 7.10 (m, 8H), 7.05 – 6.92 (m, 10H), 6.88 – 6.82 (m, 2H), 6.76 – 6.68 
(m, 2H), 5.31 (s, 4H), 3.78 (s, 3H), 3.69 (s, 3H), 2.64 (q, J = 7.6 Hz, 2H), 
2.52 (q, J = 7.6 Hz, 2H), 1.21 (t, J = 7.6 Hz, 3H), 1.12 (t, J = 7.6 Hz, 3H), 13C NMR (100 MHz, CDCl3) 
δ 160.6, 159.3, 146.0, 144.7, 144.4, 143.8, 135.7, 133.5, 133.4, 131.6, 130.2, 128.8, 128.7, 128.6, 128.2, 
128.1, 128.0, 127.6, 126.7, 125.2, 123.8, 119.9, 114.7, 114.0, 55.5, 55.3, 52.0, 28.8, 28.7, 15.5, 15.4, 
HRMS (ESI+) m/z calcd for C24H24N3O ([M+H]+) 370.1919, found 370.1915.  
 
1-(2′-Acetamido-2′-deoxy-3′,4′,6′-tri-O-acetyl-β-D-glucopyranosyl)-5-phenyl-1H-1,2,3-triazole (3la) 
81% yield, white solid, 1H NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 7.50 (s, 5H), 
6.36 (d, J = 9.7 Hz, 1H), 5.99 (d, J = 7.3 Hz, 1H), 5.87 (t, J = 9.8 Hz, 1H), 5.12 
(t, J = 9.7 Hz, 1H), 4.46 (td, J = 10.0, 7.4 Hz, 1H), 4.24 (dd, J = 12.4, 5.8 Hz, 
1H), 4.15 (dd, J = 12.4, 2.0 Hz, 1H), 3.97 (ddd, J = 10.0, 5.7, 2.0 Hz, 1H), 2.10 
(s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.73 (s, 3H), 13C NMR (100 MHz, CDCl3) δ 170.9, 170.6, 170.2, 
169.7, 140.1, 133.6, 130.2, 129.2, 129.1, 126.0, 82.3, 74.5, 71.2, 68.8, 62.4, 54.4, 23.2, 20.9, 20.8, 20.7, 
HRMS (ESI+) m/z calcd for C22H26N4NaO8 ([M+Na]+) 497.1642, found 497.1640. 
 
5-Phenyl-1-(2′,3′,4′,6′-tetra-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazole (3ma) 
73% yield, white solid, 1H NMR (400 MHz, CDCl3) δ 7.70 (s, 1H), 7.50 (s, 5H), 
5.92 (t, J = 9.4 Hz, 1H), 5.61 (d, J = 9.5 Hz, 1H), 5.28 (t, J = 9.4 Hz, 1H), 5.18 
(t, J = 9.7 Hz, 1H), 4.25 (dd, J = 12.5, 5.5 Hz, 1H), 4.17 (dd, J = 12.4, 2.2 Hz, 
1H), 3.90 (ddd, J = 9.8, 5.5, 2.2 Hz, 1H), 2.09 (s, 3H), 2.02 (s, 3H), 1.97 (s, 3H), 
1.79 (s, 3H), 13C NMR (100 MHz, CDCl3) δ 170.5, 170.3, 169.3, 168.3, 139.5, 133.5, 130.2, 129.2, 
129.2, 126.1, 83.6, 74.8, 73.4, 69.5, 67.7, 62.0, 20.8, 20.6, 20.5, 20.3, HRMS (ESI+) m/z calcd for 
C22H25N3NaO9 ([M+Na]+) 498.1483, found 498.1483. 
 
5-(Phenyl)-1-(2′,3′,4′,6′-tetra-O-acetyl-β-D-galactopyranosyl)-1H-1,2,3-triazole (3na) 
81% yield, yellowish solid, 1H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 7.56 – 
7.43 (m, 5H), 5.87 (t, J = 9.8 Hz, 1H), 5.68 (d, J = 9.4 Hz, 1H), 5.43 (d, J = 3.2 
Hz, 1H), 5.10 (dd, J = 10.2, 3.3 Hz, 1H), 4.19 – 4.09 (m, 3H), 2.06 (s, 3H), 2.04 
(s, 3H), 1.92 (s, 3H), 1.79 (s, 3H), 13C NMR (100 MHz, CDCl3) δ 170.3, 170.1, 
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170.0, 168.3, 139.2, 134.0, 129.9, 129.6, 128.8, 126.3, 85.0, 73.8, 71.5, 67.0, 66.9, 61.6, 20.7, 20.6, 
20.5, 20.3, HRMS (ESI+) m/z calcd for C22H25N3NaO9 ([M+Na]+) 498.1483, found 498.1478. 
 
1-(1′-Ethyl-2′,3′,4′,6′-tetra-O-acetyl-β-D-glucopyranosyl)-5-phenyl-1H-1,2,3-triazole (3oa) 
78% yield, white solid, 1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.53 
– 7.43 (m, 3H), 7.44 – 7.38 (m, 2H), 5.11 (t, J = 9.5 Hz, 1H), 5.01 (t, J = 
9.7 Hz, 1H), 4.91 (dd, J = 9.5, 8.0 Hz, 1H), 4.52 – 4.40 (m, 3H), 4.31 (dt, 
J = 10.2, 4.3 Hz, 1H), 4.25 – 4.18 (m, 2H), 4.04 (dd, J = 12.3, 2.3 Hz, 1H), 
3.64 (ddd, J = 9.9, 4.7, 2.3 Hz, 1H), 2.04 (s, 3H), 1.99 (s, 3H), 1.94 (s, 3H), 1.80 (s, 3H), 13C NMR (100 
MHz, CDCl3) δ 170.66, 170.16, 169.48, 169.31, 139.18, 132.75, 129.64, 129.29, 129.15, 126.68, 101.02, 
72.72, 71.92, 70.89, 68.36, 68.17, 61.77, 47.44, 20.79, 20.64, 20.61, 20.53, HRMS (ESI+) m/z calcd 
for C24H29N3NaO10 ([M+Na]+) 542.1745, found 542.1750. 
 
1-(2′,3′,6′,2′′,3′′,4′′,6′′-Hepta-O-acetyl- β-maltosyl)-5-phenyl-1H-1,2,3-triazole (3pa) 
74% yield, white solid, 1H NMR (400 MHz, CDCl3) δ 7.72 (s, 1H), 7.57 
– 7.45 (m, 5H), 5.92 (t, J = 9.5 Hz, 1H), 5.55 (d, J = 9.5 Hz, 1H), 5.44 (d, 
J = 4.0 Hz, 1H), 5.32 (td, J = 9.5, 2.6 Hz, 2H), 5.03 (t, J = 9.9 Hz, 1H), 
4.85 (dd, J = 10.5, 4.0 Hz, 1H), 4.49 (dd, J = 12.2, 2.4 Hz, 1H), 4.30 – 
4.22 (m, 2H), 4.13 (t, J = 9.3 Hz, 1H), 4.05 (dd, J = 12.4, 2.1 Hz, 1H), 
3.98 (ddd, J = 10.2, 4.0, 2.2 Hz, 1H), 3.89 (ddd, J = 9.6, 5.3, 2.5 Hz, 1H), 2.14 (s, 3H), 2.09 (s, 3H), 
2.01 (s, 3H), 1.99 (s, 3H), 1.98 (s, 3H), 1.97 (s, 3H), 1.76 (s, 3H), 13C NMR (100 MHz, CDCl3) δ 170.6, 
170.6, 170.5, 170.4, 170.0, 169.5, 168.8, 139.7, 133.2, 130.3, 129.4, 129.0, 126.1, 95.9, 82.8, 76.3, 75.0, 
72.7, 70.1, 70.0, 69.3, 68.8, 68.1, 63.0, 61.7, 21.0, 20.9, 20.8, 20.7, 20.6, 20.5, 20.3, HRMS (ESI+) m/z 











75% yield, brown oil, 1H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 7.23 – 7.17 
(m, 3H), 7.10 (s, 4H), 7.02 – 6.93 (m, 2H), 5.46 (s, 2H), 4.99 (d, J = 8.0 Hz, 1H), 
4.54 (dd, J = 13.6, 6.1 Hz, 1H), 3.65 (s, 3H), 3.11 (dd, J = 13.8, 5.6 Hz, 1H), 
2.99 (dd, J = 13.8, 6.3 Hz, 1H), 1.34 (s, 9H), 13C NMR (100 MHz, CDCl3) δ 
172.1, 155.1, 137.9, 137.9, 135.5, 133.4, 130.0, 129.0, 128.9, 128.2, 127.2, 
125.7, 80.2, 54.4, 52.5, 51.9, 38.2, 28.4, HRMS (ESI+) m/z calcd for 
C24H28N4NaO4 ([M+Na]+) 459.2002, found 459.2006. 
Methyl (S)-3-(4′-(1′′-(1′′′-ethyl-2′′′,3′′′,4′′′,6′′′-tetra-O-acetyl-β-D-glucopyranosyl)-1H-1,2,3-triazol-5′′-
yl)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate (3oo) 
65% yield, yellow solid, 1H NMR (400 MHz, CDCl3) δ 7.59 (s, 1H), 7.30 
(d, J = 8.0 Hz, 2H), 7.20 (d, J = 7.2 Hz, 2H), 5.01 (ddd, J = 19.3, 16.6, 9.5 
Hz, 3H), 4.86 (dd, J = 9.4, 8.1 Hz, 1H), 4.57 (d, J = 6.8 Hz, 1H), 4.44 – 
4.34 (m, 3H), 4.27 (dd, J = 9.2, 5.2 Hz, 1H), 4.17 (dt, J = 15.1, 5.1 Hz, 2H), 
4.01 (dd, J = 12.3, 2.1 Hz, 1H), 3.70 (s, 3H), 3.60 (ddd, J = 9.8, 4.6, 2.2 
Hz, 1H), 3.14 (dd, J = 13.8, 5.4 Hz, 1H), 3.03 (dd, J = 13.6, 6.0 Hz, 1H), 2.01 (s, 3H), 1.94 (s, 3H), 1.90 
(s, 3H), 1.73 (s, 3H), 1.36 (s, 9H), 13C NMR (100 MHz, CDCl3) δ 172.2, 170.7, 170.2, 169.5, 169.3, 
155.2, 139.0, 138.0, 132.8, 130.2, 129.4, 125.4, 101.1, 80.2, 72.8, 72.0, 70.9, 68.4, 68.2, 61.8, 54.4, 
52.5, 47.5, 38.3, 28.4, 20.9, 20.7, 20.6, 20.5, HRMS (ESI+) m/z calcd for C33H44N4NaO14 ([M+Na]+) 
743.2746, found 743.2750. 
 
2D NMR: NOESY/HSQC Study 
The regiochemical patterns of substituted 1,2,3-triazoles were determined by 1H–1H NOESY spectra, 
as depicted in Figure 3.6. Additionally, the triazole CH of 3 exhibits characteristic 13C chemical shift 
within ~133  3 ppm.34 The regiochemistry of triazoles (3da, 3ea, 3fa, 3ga, 3ja, 3ka, 3ab, 3ad, 3af, 
3ag, 3ah, 3ak, 3am, 3la, 3ma, 3na, 3oa, 3pa, 3ao, and 3oo) was confirmed by 2D NMR (NOESY 









X-ray Data of 3ah and 3ja 
The crystal was mounted under oil on a loop and X-ray diffraction data were collected with 
monochromatic synchrotron X-rays (λ = 0.66 Å, 6D UNIST-PAL beamline) with a Rayonix MX225-
HS detector. The crystal structure was solved by direct method using SHELXTL package. All non-
hydrogen atoms were refined with anisotropic displacement parameters. The hydrogen atoms were 























Table 3.6. Crystal Data and Structure Refinement of 3ah. 
Identification code 3ah 
Empirical formula C15H12N4O2 
Formula weight 280.29 
Temperature 123 K 
Crystal system Monoclinic 
Space group P21 
Unit cell dimensions 
a = 6.8000(14) Å  α = 90° 
b = 11.502(2) Å  β = 99.74(3)° 
c = 8.4630(17) Å  γ = 90° 
Volume 652.4(2) Å 3 
Z 2 
Density (calculated) 1.427 g/cm3 
Absorption coefficient 0.099 mm-1 
F(000) 123 
Theta range for data collection 2.442 to 31.490°. 
Index ranges -9<=h<=9, -16<=k<=16, -12<=l<=12 
Reflections collected 7695 
Independent reflections 4282 [R(int) = 0.1151] 
Completeness to theta = 25.242° 100.0 % 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4282 / 1 / 190 
Goodness-of-fit on F2 1.153 
Final R indices [I>2sigma(I)] R1 = 0.0628, wR2 = 0.1664 
R indices (all data) R1 = 0.0733, wR2 = 0.1726 





Table 3.7. Crystal Data and Structure Refinement of 3ja. 
Identification code 3ja 
Empirical formula C19H15N3 
Formula weight 285.34 
Temperature 100 K 
Crystal system Monoclinic 
Space group P21 
Unit cell dimensions 
a = 8.1940(16) Å  α = 90° 
b = 6.0730(12) Å  β = 104.96(3)° 
c = 15.178(3) Å  γ = 90° 
Volume 729.7(3) Å 3 
Z 2 
Density (calculated) 1.299 g/cm3 
Absorption coefficient 0.079 mm-1 
F(000) 310 
Theta range for data collection 2.573 to 31.531°. 
Index ranges -12<=h<=12, -0<=k<=8, -22<=l<=22 
Reflections collected 4332 
Independent reflections 2564 [R(int) = 0.0971] 
Completeness to theta = 25.242° 97.6 % 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2564 / 1 / 199 
Goodness-of-fit on F2 1.203 
Final R indices [I>2sigma(I)] R1 = 0.0566, wR2 = 0.1853 
R indices (all data) R1 = 0.0818, wR2 = 0.2176 





Identification of Ni complexes by EPR spectroscopy and HRMS 
 
Scheme 3.7. Possible transformations of Ni complexes based on the experimental results and literature 
precedent. 
EPR spectroscopy 
Sample preparation: A solution of Cp2Ni (0.1 mmol) and Xantphos (0.1 mmol) in toluene (2 mL) was 
stirred at 20 ºC for 1 h, during which the color of the reaction mixture changed from deep green to 
brown. After filtration, samples were taken from the filtrate. 
EPR spectroscopy: EPR spectra were obtained on a Bruker EMXplus 9.5/12 spectrometer at 295 K. 
Typical EPR spectral parameters were an X-band microwave frequency of 9.385 GHz, a modulation 
frequency of 100 kHz, a modulation amplitude of 5 G, and a microwave power of 6.33 mW. 
 
Figure 3.2. EPR spectrum of a sample from the reaction between Cp2Ni and Xantphos in toluene (X-
band microwave frequency, 9.385 GHz, modulation frequency, 100 kHz, modulation amplitude, 5 G, 
microwave power, 6.33 mW, temperature, 295 K, 10 scans). 
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The EPR spectrum of the product mixture shows a triplet resonance signal centered at g = 2.088 with a 
hyperfine splitting constant of a = 104 G. These parameters are similar to those reported for related Ni 
complexes, such as NiCp(dppe) (g = 2.068, a = 122 G),40 suggesting that CpNi(Xantphos) was formed. 
 
HRMS Study 
HRMS (ESI+) spectra were obtained on a Thermo Scientific Q Exactive Plus Hybrid Quadrupole-
Orbitrap mass spectrometer. We prepared samples by diluting the EPR sample with HPLC-grade 
methanol. After filtration, sample was taken from the filtrate. 
 
Figure 3.3. HRMS study: (a) wide range data, and (b) isotope distributions of [CpNi(Xantphos)]+.  
[Ni(Xantphos)2+2Na]2+ (ESI+, m/z) calcd for C78H64Na2NiO2P42+ ([M+2Na]2+) 630.1500, found 
630.1638, [CpNi(Xantphos)]+ (ESI+, m/z) calcd for C44H37NiOP2 ([M]+) 701.1667, found 701.1671. 
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Preparation of 4-Cyano-1,5-Disubstituted 1,2,3-Triazoles and Establishment of Chemoselective 
Sequential 1,2,3-Triazoles via NiAAC 
 
4.1. Abstract 
In the area of conjugate chemistry, internal alkynes including two different cargoes are attractive targets. 
But their poor regioselectivity when conjugated with azides are one of challenging factors. 
Propynenitriles, which own electron-withdrawing group, are considerable candidates to make exclusive 
1,2,3-triazoles. After cross-coupling with azide, a nitrile group on triazole could be transformed and 
conjugated simply with other functional group. Here, the NiAAC methodology was applied to 
cyaonalkyne conjugation to achieve high yields and selectivity under mild conditions. The broad 
substrate scope also supports its tolerance and versatility. Additionally, preference order between 
cyanoalkyne and alkyne was figured out that propynenitriles are solely consumed, followed by the 
terminal or internal alkyne consumption. The tendency is applied in the establishment of sequential 
double copper- or nickel- catalyzed cycloadditions with high yields and selectivity. Methodologies 
presented in this chapter are potential building blocks for the development a programmed synthesis for 
complex molecules. The data described below are based on preliminary research. 
4.2. Introduction 
Azide and alkyne are versatile functional groups in applied science because of their chemical inertness, 
orthogonality, and small size. Cross-coupling of the corresponding two groups produce 1,2,3-triazoles, 
promising candidates in pharmaceutical studies. Research to prepare the five-membered heterocycle 
has led to various routes with or without transition metal catalysts. For example, copper1 and silver2 
complexes catalyze the regioselective formation of 1,4-disubstituted 1,2,3-triazoles, and ruthenium3 and 
nickel4 catalysts facilitate preparation of the corresponding 1,5-disubstituted core. Compared to the 
astonishing development of terminal alkyne conjugation, internal alkynes have not been chosen as 
coupling partner because of relatively limited accessibility. Hetero-functionalized internal alkynes 
having specific dipole moments are primarily used to synthesize regioselective 1,4,5-trisubstituted 
triazoles. Azides could be paired with thioalkynes in the presence of iridium5 or ruthenium6 catalysts 




4-Cyano 1,2,3-triaozles are potentially important scaffolds to load three different cargoes by coupling 
and modifying nitrile groups. But there is no typical method that can be applied to a broad substrate 
scope and mild conditions to access the corresponding triazoles (Scheme 4.1). Wang9 and Reddy10 
groups independently reported that enamine or enolate prepared by mixing carbonyl cyanide and 
organocatalysts (e.g., diethyl amine, DBU) in situ, could make dipolar cycloaddition. Compared to the 
capability of various carbonyl reactant derivatives, available azides are limited to aryl and tosyl 
groups.11 In 2018, Zhu group suggested enhanced synthesis of 1-cyanoalkynes, and ruthenium catalyzed 
azide−propynenitrile cycloaddition.12 They utilized pentamethylcyclopentadienyl (Cp*) ruthenium(II) 
catalyst and conditions, which are already published in 1,5-disubstituted 1,2,3-triazole synthesis.13 
Accessibility in preparing cyanoalkynes was enhanced, but method still suffered from long reaction 
time, usage of organic solvents, and elevated temperature. 
Herein, I report a general synthetic method for the preparation of 4-cyano 1,2,3-triazoles using 
Cp2Ni/Xantphos reagents. A broad substrate could be conjugated rapidly in water at room temperature. 
Based on the preference test, I could suggest several sequences using metal catalyzed cross-coupling to 
establish preparation of chemoselective complexes including different 1,2,3-triazole cores. Figures and 
tables below are preliminary data, subsequent repeat experiments could improve precision and quality 




Scheme 4.1. Schematic representation of precedent and this works in synthesis of 4-cyano-1,5-
disubstitutd 1,2,3-triazoles.  
4.3. Results and discussion 
Optimization process was conducted with 2,6-difluorobenzyl azide 1a and 3-phenyl-2-propynenitrile 
2a (Table 4.1). With the consideration of previous paper regarding nickel catalyzed cycloaddition,4 I 
decided initial standard conditions. Reaction screening showed 20 mol% of metal and ligand generated 
more 3aa compared to 10 mol % case (entry 1 and 5). Reaction times are critical factors in optimization, 
resulting in quantitative total yield on entry 4. Reactions conducted in water showed generally lower 
yields compared to corresponding cases in toluene. Optimized reaction conditions are 10 mol % of 
nickelocene, Xantphos and equimolar amount of cesium carbonate at room temperature and 24 h in 
toluene or water. Selectivity ratios (~13:1) are slightly poor under various conditions, requiring column 
chromatography to exclude isomer 4aa. The characteristic difference between 4-cyano triazoles and 5-
cyano triazoles was measured by 1D NMR, 2D NMR and single-crystal X-ray diffraction measurement. 
 
Table 4.1. Optimization of reaction conditions.a 
Then I investigated the substrate scope with various functional groups introduced azide and 
cyanoalkyne derivatives under optimized conditions. Additionally, yields obtained in toluene and water 
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are given to show solvent tolerance in the nickel catalyzed reaction. Incomplete substrate tables are 
attached at this stage (Scheme 4.2). Generally, entries require a day for full conversion of reactants, but 
benzyl azide 1b is totally consumed within 2 h. Entries in aqueous media have weakness in yield 
because of poor solubility of reagents. Various azides (1a−1h) were screened to check the production 
of corresponding 4-cyano-1,5-disubstituted triazoles in the aspect of yield and selectivity. Different 
functional groups including fluoro-, trifluoromethyl-, hydroxy-, and nitro moieties were examined and 
various structures such as secondary, polycyclic, aliphatic, and heterocycle moieties are also potential 
candidates for supporting the generality of the method. In cyanoalkyne derivatives test, I could secure 
group tolerance, but selectivity ratios were different from poor 3:1 to excellent 18.2:1. Conjugation of 
biomolecules (e.g., carbohydrates, amino acids) would be feasible via Cp2Ni/Xantphos catalytic system. 
 
Scheme 4.2. Substrate scope of nickel catalyzed azide−cyanoalkyne cycloadditiona 
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The reactivity of cyanoalkynes in NiAAC was investigated by comparison with phenylacetylene 
(Scheme 4.3). Tests were conducted by mixing azide 1b, cyanoalkyne 2a, and terminal alkyne 2g in 
equimolar amounts (1:1:1) under standard reaction conditions. An initial assumption is that triazole 3ba 
and 5bg could be synthesized as similar amounts because each alkyne conjugation to azide showed 
comparable reaction times. But interestingly, azide 1b is fully consumed for the exclusive conjugation 
with 2a to elicit 3ba (87%) and 4ba (8%). Preference results are even more favorable compared to the 
corresponding test in RuAAC, showing a 9:1 ratio of 3ba and 5bg.12 The addition of extra 1b proved 
that terminal alkyne 2g was not damaged during the reaction, because it could be conjugated with azide 
in the absence of cyanoalkyne (Scheme 4.3, second line). There is a catalytic degradation in first click 
reaction, and additional nickelocene/Xantphos are essential for sequential cycloadditions (third line). 
Electron-withdrawing ability of cyanoalkynes or mechanistic difference when coordinated to metal 
complexes are potential reasons of preferences, requiring supplementary experimental evidence. 
 
Scheme 4.3. Reactivity comparison test between cyanoalkyne and terminal alkyne. 
 
Despite wide applications of CuAAC, sequential click reactions are poorly developed because of its 
strong reactivity. Some outstanding methodologies utilized different chemoselectivity of azides14 (metal 
chelating effect to nitrogen, explained in Figure 1.11) or diverse alkyne pairs (alkyne versus 
cyclooctyne15, or alkyne versus trimethylsilyl group protected alkyne16). The development of new 
sequential double click methods expands chemical tools to access complex molecules by one-pot and 
non-chromatographic purifications. Reactivity preferences described in scheme 4.3 give great 
importance to a molecular core 2h, including terminal alkyne and cyanoalkyne (Scheme 4.4A). Copper-
catalyzed cycloaddition elicits conjugation of terminal alkyne and azide, because CuAAC could not be 
reacted with internal alkyne moieties, on the other hand, nickel-catalyzed addition could produce 
cyanoalkyne−conjugated molecules exclusively. Remaining alkyne moiety would be coupled with extra 
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azide cargoes to furnish chemoselective sequential double click reactions. Scheme 4.4B represents 
methods utilizing molecule 2i, having trimethylsilyl (TMS) group protected alkyne and cyanoalkyne. 
Because nickel complex could not catalyze the coupling of TMS protected internal alkynes, 4-cyano 
1,2,3-triazoles were formed exclusively, subsequent deprotection by silver catalysts enabled sequential 
1,3-dipolar cycloadditions. With the combination of different transition metal catalyzed cycloadditions, 
conceptually, various triazole isomers and more complex molecules could be prepared with multiple 
click reactions. 
 




Reactions were checked by thin-layer chromatography (TLC) using Merck silica gel 60F254 glass plate 
with the help of ultra-violet lamp (254 nm), or potassium permanganate solution. Flash column 
chromatography was carried out using Merck silica gel 60. All reagents were purchased from standard 
suppliers (Sigma-Aldrich, Alfa Aesar) and used without further purification. 1H, 13C, and 19F NMR 
spectra were recorded on a Bruker Avance III HD (400 MHz for proton, 100 MHz for carbon). Chemical 
shifts are given on the δ-scale in ppm, and residual solvent peaks were used as internal standards. 
74 
 
Synthesis of organic azides 
Generally, SN2 type reaction is applied in preparation of organic azides. By simple mixing organic 
bromide (1.0 equiv) and sodium azide (1.5 equiv) in aprotic solvent DMSO or a mixture of 1:3 
water/acetone solution, desired starting materials are made after stirring 24 hours at room temperature. 
Detailed experimental procedures are included in reference paper.4 Sodium azide is extremely toxic and 
explosive. Avoiding metal spatula during azide experiments are recommended. 
Synthesis of cyanoalkynes 
 
Scheme 4.5. Preparation of propynenitriles. 
Cyanoalkynes are prepared through two-step reactions from iodo compounds (Scheme 4.5). At first, 
propargyl alcohol was introduced via Sonogashira reaction in the presence of palladium catalysts. To a 
suspension of Pd(PPh3)2Cl2 (70 mg, 0.1 mmol) and CuI (38 mg, 0.2 mmol) in trimethylamine (40 mL), 
iodo-compounds (10 mmol) and propargyl alchohol (0.64 mL, 10.9 mmol) were added at room 
temperature, and stirred 8 hours under nitrogen atmosphere. Crude solutions were filtered through celite, 
following silica column chromatography to purify intermediate compounds. After column purification, 
intermediate propargyl alcohols could be transformed to corresponding nitriles through one-pot 
oxidative conversion.17 To an acetonitrile/water (9:1) solvent 20 mL, (2,2,6,6-tetramethylpiperidin-1-
yl)oxyl (TEMPO) (44 mg, 0.28 mmol), iodosobenzene diacetate (4.02 g, 12.4 mmol), and ammonium 
acetate (1.75 g, 22 mmol) were dissolved under nitrogen atmosphere. Intermediates (5.67 mmol) were 
added and stirred 30 minutes at room temperature. After water/diethyl ether separation, column 




Scheme 4.6. Preparation of propynenitriles 2h and 2i. 
Compound 2h and 2i are prepared from 1,4-diiodobenzene with similar methodology. One portion of 
iodo group was replaced with propargyl alcohol, then the other iodo group was converted to 
trimethylsilylacetylene. Compound 2h are easily prepared by eliminating trimethylsilyl group with 
silver metal complex such as silver nitrate or silver trifluoromethanesulfonate. 
General Procedure for the nickel catalyzed cross-coupling 
To a mixture of nickelocene (10 mol%) and Xantphos (10 mol%) in water or toluene (2.0 mL), 
cyanoalkyne 2 (1.2 equiv, 0.46 mmol), cesium carbonate (1.0 equiv, 0.38 mmol) and organic azide 1 
(1.0 equiv, 0.38 mmol) were added and stirred at rt. After 24 hours, the suspension was diluted with 
DCM, washed with water, and dried over sodium sulfate. The desired product was purified by flash 
column chromatography and dried in vacuo. 
Characterization data 
At this stage, I’ve measured some preliminary data of 1H NMR spectra. Other characterization data 








Compound 2i: 1H NMR (400 MHz, CDCl3) δ 7.56 – 7.52 (m, 2H), 7.50 – 7.45 (m, 2H), 0.26 (s, 9H). 
 
Figure 4.1. 1H NMR (400 MHz, CDCl3) of the compound 2i. 
 
Compound 2h: 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.54 (m, 2H), 7.54 – 7.49 (m, 2H), 3.30 (s, 1H). 
 




Compound 3ba: 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.49 (m, 3H), 7.37 – 7.27 (m, 5H), 7.11 – 7.04 
(m, 2H), 5.55 (s, 2H). 
 
Figure 4.3. 1H NMR (400 MHz, CDCl3) of the compound 3ba. 
 
Compound 3ca: 1H NMR (400 MHz, CDCl3) δ 7.63 – 7.53 (m, 3H), 7.42 – 7.34 (m, 8H), 7.25 – 7.17 
(m, 4H), 6.70 (s, 1H). 
 
Figure 4.4. 1H NMR (400 MHz, CDCl3) of the compound 3ca. 
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Compound 3fa: 1H NMR (400 MHz, CDCl3) δ 7.60 – 7.49 (m, 3H), 7.37 – 7.31 (m, 2H), 7.09 – 7.02 
(m, 2H), 7.02 – 6.92 (m, 2H), 5.52 (s, 2H). 
 
Figure 4.5. 1H NMR (400 MHz, CDCl3) of the compound 3fa. 
 
Compound 3ga: 1H NMR (400 MHz, CDCl3) δ 7.53 – 7.42 (m, 2H), 7.26 (d, J = 6.8 Hz, 1H), 7.13 (d, 
J = 8.1 Hz, 1H), 5.54 (s, 1H). 
 
Figure 4.6. 1H NMR (400 MHz, CDCl3) of the compound 3ga. 
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Compound 3ha: 1H NMR (400 MHz, CDCl3) δ 7.66 – 7.54 (m, 5H), 5.87 (t, J = 9.4 Hz, 1H), 5.61 (d, J 
= 9.5 Hz, 1H), 5.28 (dd, J = 11.7, 7.2 Hz, 1H), 5.16 (t, J = 9.8 Hz, 1H), 4.20 (ddd, J = 14.8, 12.6, 4.0 
Hz, 2H), 3.92 (ddd, J = 10.0, 5.6, 2.3 Hz, 1H), 2.09 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H), 1.82 (s, 3H). 
 
Figure 4.7. 1H NMR (400 MHz, CDCl3) of the compound 3ha. 
Compound 3bb: 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.13 (m, 5H), 7.05 – 6.97 (m, 2H), 6.96 – 6.88 
(m, 2H), 5.45 (s, 2H), 3.77 (s, 3H). 
 
Figure 4.8. 1H NMR (400 MHz, CDCl3) of the compound 3bb. 
80 
 
Compound 3bc: 1H NMR (400 MHz, CDCl3) δ 8.38 – 8.31 (m, 2H), 7.56 – 7.49 (m, 2H), 7.38 – 7.27 
(m, 3H), 7.11 – 7.02 (m, 2H), 5.60 (s, 2H). 
 
Figure 4.9. 1H NMR (400 MHz, CDCl3) of the compound 3bc. 
 
Compound 3bd: 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 8.5 Hz, 2H), 7.32 
(dd, J = 5.1, 1.9 Hz, 3H), 7.07 – 7.00 (m, 2H), 5.58 (s, 2H). 
 
Figure 4.10. 1H NMR (400 MHz, CDCl3) of the compound 3bd. 
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Compound 3be: 1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.6 Hz, 2H), 7.33 
– 7.27 (m, 3H), 7.09 – 7.03 (m, 2H), 5.56 (s, 2H), 4.41 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H). 
 
Figure 4.11. 1H NMR (400 MHz, CDCl3) of the compound 3be. 
Compound 3bf: 1H NMR (400 MHz, CDCl3) δ 8.77 (d, J = 4.0 Hz, 1H), 8.57 (s, 1H), 7.64 (d, J = 7.8 
Hz, 1H), 7.45 (dd, J = 7.4, 5.0 Hz, 1H), 7.29 (dd, J = 9.5, 6.0 Hz, 3H), 7.05 (dd, J = 6.3, 2.7 Hz, 2H), 
5.57 (s, 2H). 
 




1H NMR (400 MHz, CDCl3) δ 7.54 – 7.49 (m, 2H), 7.27 – 7.18 (m, 5H), 7.03 – 6.97 (m, 2H), 5.47 (s, 
2H), 0.20 (s, 9H). 
 
Figure 4.13. 1H NMR (400 MHz, CDCl3) of the compound 3bi. 
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